Should Global Health Initiatives Have a Termination Date? 07/06/2024 Sophia Samantaroy From left: Katerini Storeng, Justice Nonvignon, Anders Nordström, and Mercy Mwangangi discuss the future of GHIs at a Geneva Graduate Institute event. One of the world’s largest global health initiatives (GHI), vaccine alliance Gavi, started in a UNICEF basement with a staff of five people. Nearly 25 years later, Gavi has grown into one of the most influential players on the global health stage, driving progress on key global health challenges. Yet several experts on global health finance contend that large non-UN multilateral health organizations like Gavi and Global Fund need to gradually turn more of their functions to countries – and devolve into less costly, more country-based institutions. The Geneva Graduate Institute hosted a frank conversation on the future of GHIs alongside the 77th World Health Assembly and Gavi and the Global Fund’s soon-to-be launched “replenishment” campaigns. GHIs have been accused of fragmenting global health efforts, challenging the authority of the World Health Organization (WHO) and privileging donor and private-sector interests while evading accountability. Remarkable achievement but little transparency In the nearly 25 years their establishment, global health initiatives have continued to expand their mandates. Gavi and the Global Fund, the largest of these GHIs, “really challenged the established ways of working through the World Health Organization, of the traditional multilateral system,” said Professor Katerini Storeng from the University of Oslo’s Centre for Development and the Environment. “They did so specifically by giving additional seats at the table to commercial companies, civil society organizations and to philanthropic foundations,” she said. This novel private-public partnership “fundamentally reshaped global health governance around private sector principles like innovation, technological solutions, and the protection of intellectual property rights,” said Storeng. Not only did GHIs introduce a private sector mentality to global health financing, but their model was “quickly embraced,” according to Storeng. One of the most recent examples of the application of the model was with the Gavi-directed global COVAX campaign during the COVID-19 pandemic. However, Storeng noted that the pandemic reignited old debates, including around how these partnerships are dominated by a handful of powerful GHIs and “the apparent conflict of interest arising from the inclusion of for profit actors into formal institutions of global health governance.” Experts have reiterated calls for better coordination between global health partnerships and for their greater alignment with national health plans and priorities. While others have rejected such calls for incremental change asking for more radical reform or even present organizations to be together. Three main developments have completely altered the GHI landscape, namely a shift towards bureaucratization, expanded mandates, and shifting cooperation with other partners, according to Antoine de Bengy Puyvallée, a PhD Fellow at University of Oslo’s Centre for Development and the Environment. GHIs have moved from being coalitions to completely separate organizations with increasingly broader missions. Furthermore, Puyvallée notes that budgets have grown “astronomically,” tripling from 2005 to 2015, meaning more staff and a greater physical footprint in the global health hotspot of Geneva. Their CEOs are now public figures, and their missions now encompass a wide range of goals beyond their original mandates. Gavi, for example, has expanded its activities to include diagnostics not just vaccinations, noted Puyvallée. “You see this journey from vaccinating children to strengthening health systems,” he said. The problem with this growth, however, is the lack of accountability. “Are the boards in control?” While global health initiatives like the Global Fund have significantly contributed to global health successes, experts argue for increased self-reliance among GHI funding recipients. “Moving forward it is wise to think of new ways to keep these partnerships accountable together – a coordination mechanism that goes beyond the traditional ways of being governed by their own boards – otherwise it’s very difficult for accountability,” concluded Puyvallée. The Global Fund says that its programs have saved 59 million lives since 2002, making significant strides in reducing deaths from HIV, TB, and malaria. Its 2022 numbers show that HIV prevention services increased by 22% compared to 2021, and the number of people diagnosed and treated for TB increased by 26%. Calls for transparency and accountability Making these GHIs more transparent and accountable requires five key strategic shifts, according to Mercy Mwangangi, director of Health Systems Strengthening at AMREF Health Africa, and former co-chair of the Future of Global Health Initiatives. These are: investing in primary healthcare, play a catalytic role in strengthening domestic resources, champion for equity when mandates are expanded, achieve strategic and operational coherence, and mobilize research and development. These five shifts were identified by the Lusaka Agenda, an international and multi-stakeholder dialogue. Mwangangi noted that the Global Fund and Gavi now have a joint partnership around malaria vaccine and health systems strengthening, but asked: “How do we ensure that these shifts lead to in-country implementation?” She stressed the need to keep country-level changes and implementation at the forefront through strengthened partnerships “otherwise we’ll just keep going round and round in circles.” Mwangangi also called for the widespread adoption of the Lusaka Agenda to ensure that countries have a bigger voice and agency in the GHI ecosystem, but was optimistic about GHI reform. “The boards have actually taken ownership of this issue and have shown interest in the Lusaka Agenda,” she added. However, Anders Nordstrom, a founding member of the Global Fund and former WHO Director General, argued that there is much to do to improve the transparency and accountability of GHIs. “The board of the Global Fund should actually discuss the yearly results report. I mean, for business, that’s one of the core responsibilities of a board. You should approve the annual report. “That is not happening with the Global Fund. You approve the annual financial statement. There’s no link in between where you spent the money and the annual report. So in their annual report, there are no financial figures. And the annual report is very, very good, actually, but the board is not including it in discussion.” Nordstrom went on to explain that if the boards do this, they could then “discuss the efficiency and effectiveness of the use of the money.” Self reliance and political responsibility Africa CDC in Addis Ababa, Ethiopia – is a promising way for countries to domestically invest in strengthening their health systems. For countries historically on the receiving end of support from GHIs, there has been a growing concern about health systems independence. “Why should initiatives like Gavi buy our basic commodities?” asked Professor Justice Nonvignon, head of Health Economics Unit at Africa CDC and part of the University of Ghana’s Health Economics department. Nonvignon argued that countries like Ghana need to domestically fund more robust health efforts, and wean themselves off of dependency. Instead of a reliance on GHIs for basic needs, countries should provide domestic funds to buy these commodities, which range from syringes to drugs and vaccines, argued Nonvignon. These countries have the means to channel funding to health if they choose to prioritize it, added Nordstrom. “There are plenty of resources,” he said, noting that while working in Sierra Leone he was told that “it’s quite a rich country, plenty of diamonds and rare minerals. But where is that money?” Mwangangi, who works closely with the Kenyan government, shared that it is incredibly difficult for African nations to transition off this dependency. “As long as there’s no sunset clause, as long as there’s no forced transition plans and more forced graduation plans, the Ministry of Finance will not move,” she said. Reducing reliance on aid, while difficult in the short-term, is a must, said Nonvignon, because it increases a country’s resilience and ability to act fast in an emergency. “Cholera is devastating huge populations across central and southern Africa. Where is the time to send a proposal to a fund based in Washington DC or in Geneva?” asked Nonvignon. “Why is the Global Fund situated in Geneva and not in Nairobi? Why is the Global Fund not in Addis Ababa instead of Geneva? Because it gives a tremendous amount of power.” In response, Nordstrom noted that much of the global health initiative ecosystem is highly political and “the power is not with the secretariat, it’s not with the directors, it’s with the governments that provide the funding.” “I’m worried that we’ve got the epidemiology wrong… the majority of people are losing their lives to non-communicable diseases. And the global health partnerships and community are not addressing that at all,” he said, adding that the GHI community has also failed to include the effects of a changing climate. Sunsetting GHIs by 2030? Nonvignon proposed sunsetting GHIs by 2030, because they have a “fundamental design flaw” in that they were established with no end date in mind. “We are beginning to see an increase in the desire of our member states [of Africa CDC] to invest money…we need to push countries to take more responsibility.” He noted that the pandemic prompted countries to increase their domestic spending on health, which will increase their long-term financial sustainability but cautioning that reducing aid from GHIs should not mean that philanthropies fill in the gap. African countries must “step up,” through regional groupings such as the African Union, he added. Putting the “onus” on countries themselves will help build global health independence – but countries need to domestically fund their own health efforts, said Mwangangi. While a termination date for donors may seem drastic, it will at least create the space for conversation about the sustainability of GHIs, and the ability of countries to find their health financing footing. Image Credits: S. Samantaroy/HPW, GAVI, The Global Fund, Africa CDC . Zimbabwe Struggles With Rising Diabetes – And Lack of Data on Prevalence Amongst Children 07/06/2024 Jeffrey Moyo A health worker tests a patient for diabetes. Like most African countries, non-communicable (NCDs) diseases, including diabetes, is increasing in Zimbabwe. And children are increasingly among the cases that go undetected or treatment until severe symptoms emerge. HARARE, Zimbabwe – Ten-year-old Tadisa Sayi already contends with diabetes and when his blood sugar levels spike his mother, Naume Shereketo, endures the mood swings induced by his condition. Three years ago, Shereketo, a single mother of two, discovered the root cause of her son’s misery during a severe bout of illness. “It was in 2021. He was weak and vomiting. When I went to the hospital with him, doctors told me he was diabetic,” Shereketo told Health Policy Watch. “He always says: “Mama, I’m weak’, and some other time he is harsh,” said Shereketo. Shereketo, a vegetable vendor on the streets of Harare, faces ballooning costs to attend to her son’s special dietary needs. She struggles to provide the specific foods required for her son’s health. For Sayi, a grade four learner, fruit, vegetables, milk and high-fibre foods, have become a regular but costly part of his diet, costing his mother between $60 and $80 monthly. Shereketo is puzzled about her son’s diabetes. No one else is diabetic in her family or the boy’s paternal side. Dr Life Zambezi, the boy’s doctor, confirmed that Sayi had Type 1 diabetes, and said that this can be challenging to manage in young children due to limited support at the community level as well as the difficulty of maintaining strict insulin routines. Type 1 diabetes, which causes glucose (sugar) in one’s blood to become too high, happens when a person’s body cannot produce a hormone called insulin that controls blood glucose. Changes in diet also cause rise in Type 2 diabetes While Type 1 diabetes is generally the result of a genetic condition, children also are being increasingly affected by Type 2 diabetes, as a result of changing diets and lifestyles, according to the UN children’s agency, UNICEF. Type 2 diabetes typically develops as a result of sedentary lifestyles, obesity and unhealthy eating habits, Zambezi notes. While it’s on the rise in most African countries, and usually associated with adults, he’s seeing more such cases among children. “Of late, children are also getting Type 2 diabetes, mainly caused by the changes in lifestyle. There is a rise in poor eating habits among children. In most cases they eat processed and unhealthy food leading to childhood obesity and eventually type 2 diabetes,” said Zambezi. But diabetic children like Sayi are too often only diagnosed only when they have developed a severe crisis, such as a diabetic coma. “NCDs in children result from a combination of genetic, environmental and behavioural factors,” Health and Child Care Deputy Minister Dr John Mangwiro explained at the launch. “When a young child is diagnosed with a non-communicable disease, this implies long-term treatment.” Dr Life Zambezi says that the high cost of insulin has made life miserable for people with diabetes, many of who cannot afford the life-saving medication. Diabetes incidence in Zimbabwe soaring – although data remains spotty Approximately 537 million people worldwide are living with diabetes, according to the according to the International Diabetes Federation (IDF), an umbrella organisation of over 240 national diabetes associations in 160 countries and territories globally. That includes 422 million people worldwide suffer from type 2 diabetes, the majority living in low- and middle-income countries, according to WHO, of the disease that kills 1.5 million people every year. That includes approximately 106,400 adults in Zimbabwe living with diabetes Type 1 and 2, a prevalence of 1.5% in the adult population of about 7.1 million, according to the International Diabetes Federation (IDF), an umbrella organisation of national diabetes associations in 160 countries and territories. However, IDF’s local member, the Zimbabwe Diabetic Association, says that’s a woeful underestimate. It estimates that as many as 10 out of every 100 people in Zimbabwe’s population of 17 million had diabetes, including children, as of 2017. But many cases go undiagnosed until the child or adult in question becomes seriously ill. A 2014 meta-analysis also suggests diabetes incidence has grown exponentially. Prior to 1980, the prevalence of diabetes in Zimbabwe was just 0.44 %, while after 1980 the prevalence was 5.7 %, according to that systematic review. By 2018, prevalence was estimated at 8.5%, according to yet another study. As of 2016, Zimbabwe had the third highest estimated per-person cost of diabetes care in sub-Saharan Africa. Insulin’s exorbitant prices also cause many to miss out on essential medication, exacerbating their condition and long-term health risks, Zambezi said. Treatment at primary health care level is spotty Treatment in primary health clinics remains spotty, the studies also suggests. One small study comparing treatment in primary versus hospital facilities in Harare, the capital city, found that more patients treated at hospital outpatient clinics ahd received some form of diabetes self-management education (DSME), and had higher levels of diabetes knowledge, as compared to those treated in primary care facilities. At the same time, people who had consulted a dietician had the best levels of diabetes knowledge and self-care routines. “Dietitian-led interventions significantly improved both knowledge and practices, highlighting a need to scale up dietetic intervention, particularly in primary clinics where limited interventions occur,” concluded the July 2019 study led by a researchers at the University of Cape Town and the University of Zimbabwe’s Department of Community Medicine. “Though improvements have been made in self-management therapies, there seems to be a high prevalence of hospital admissions with relapse of symptoms in Zimbabwe. Relapse in diabetes predicts poor prognosis,” concluded another, 2021 study, led by the University of Zimbabwe’s Department of Nutrition. Recognizing those gaps, UNICEF in 2022 launched an initiative in five countries including Zimbabwe, to focus on NCD prevention, detection, treatment and support, particularly in children and young adults. As part of the grant, funded by the pharma firm, Eli Lilly, Zimbabwe’s Ministry of Health received $2.5 million to educate community health workers and increase support and understanding of various NCDs including diabetes in children. Late detection and poor management results in adult complications Diagnosed with diabetes 20 years ago, 30-year-old Tariro Chiripanyanga is now contending with end-stage kidney disease as a result of poor management of her diabetes. But until earlier detection and prompt treatment become more of the norm, many children will continue end up with severe complications in early adulthood, Zambezi observed. One such case is Tariro Chiripanyanga. The youngest of four siblings, Chiripanyanga was diagnosed with Type 1 diabetes at the age of 10. Today Chiripanyanga is now facing end-stage kidney disease, although she is only 30 years old. “I was still too young to understand what it meant or how it would affect my life, but that’s when my life changed forever,” Chiripanyanga told Health Policy Watch. Apart from living with diabetes since childhood, Chiripanyanga was diagnosed with kidney disease six years ago. She needs $30,000 for a kidney transplant, a financial burden neither she nor her family can bear. Chiripanyanga’s diabetes has already led to partial blindness, forcing her to drop out of university. “My life depends on peritoneal dialysis which costs $1,750 monthly,” Chiripanyanga said. “I depend on dialysis until I can get money for a transplant which costs an estimated $30,000 in India.” Image Credits: Muhidin Issa Michuzi, Jeffrey Moyo. One Health is a ‘One World’ Agenda, Even as Negotiators Wrangle Over Inclusion in WHO Pandemic Accord 06/06/2024 Elaine Ruth Fletcher ‘There is no one way to implement One Health solutions:’ Eric Comte, at podium with panelists describing country experiences: (left to right) Benjamin Roche, Chloe Astbury, Arlette Dinde and moderator, Nina Jamal. Is One Health really an agenda of only the Global North? Panelists at an event last week, hosted by the Geneva Graduate Institute’s Global Health Center, think otherwise. They talked about how developing countries are putting One Health principles into practice to head off future disease outbreaks. One Health is critical to future prevention of outbreaks and pandemics, and wider application of One Health principles should be a common agenda of both the global North and South – even if negotiators continue to wrangle over its inclusion in the still-unfinished World Health Organization (WHO) pandemic agreement. Those were key messages emerging from a dialogue co-sponsored by the Global Health Center (GHC) together with the Geneva Health Forum on the sidelines of last week’s World Health Assembly. At WHA, negotiators received a new mandate from member states to continue talks to conclude a pandemic accord by the 2025 WHA at the latest. The talks are set to resume in July. The Geneva Health Forum, convened by the University of Geneva and partners on the first three days of the 2024 World Health Assembly, brings together key global health scientists and policymakers with medical practitioners and other field actors. During the last frenzied weeks of negotiations just before WHA, the inclusion of references to One Health principles in Article 5 of the draft text spurred opposition from some low- and middle income countries (LMICs) as well as some civil society organizations. In late May, 68 CSOs called on negotiators to ‘Reject One Health Instrument’ in the pandemic agreement. They argued that One Health provisions intended to boost pathogen surveillance and pandemic prevention could also enable developed countries to erect new trade barriers and data demands on developing countries, and impose more costly pandemic preventive measures which poorer countries could not afford to implement. Over 120 experts and civil society proponents shot back with an open letter of their own. They asserted that better recognition of One Health principles and practices is critical to prevent more deadly spillover of zoonotic diseases into human populations, which could cause the next pandemic, as well as more locally disease outbreaks that typically kill people in LMICs first of all. Many One Health projects already taking place in Africa, South-East Asia Nina Jamal, Four Paws International. “Is One Health really a global North agenda?” asked moderator Nina Jamal, International Head of Pandemics and Campaign Strategies at Four Paws International, which also co-sponsored the event. The soft-spoken Jamal, a Lebanese-Austrian with a wealth of experience straddling such ‘North’ and ‘South’ polarities, has become one of the leading advocates One Health in the pandemic agreement, patiently sitting through countless late-night sessions, and speaking one-on-one with delegates about their views and concerns over more than two years of negotiations. “The perception is that One Health involves a set of obligations imposed by high income countries on low-income ones. But is all the knowledge and expertise on One Health in the global North?” asked Jamal. At the GHC event, researchers working in countries as diverse as the Cote d’Ivoire, Guinea, Mexico, China and the Democratic Republic of Congo, described how they they are putting One Health principles into practice to promote better animal surveillance, reduced deforestation, and improved practices around wildlife management in food markets and trade – and document related health benefits. Most recent outbreaks linked to lack of ‘One Health’ measures Live chickens await slaughter at a traditional market in Lanzhou, China. Along with mammals, live poultry also harbor pathogens that can infect humans, in instances such as the H5N1 outbreak of avian influenza of the late 1990s. Most recent outbreaks of disease that have hit developing countries harder than developed ones are somehow related to an overall dearth of One Health measures that needs to be addressed, the experts asserted. Examples range from Ebola, Lassa fever and mpox in Africa, to SARS and Nipa virus in Asia, and expanding circles of dengue virus, Chagas disease, in Latin America. Countries in the global North are not immune either. That was evident in the 2009 H1N1 [swine flu] pandemic, that first appeared in Mexico and the United States, and ultimately infected up to 80 million people. More recently the US has seen a surge in H5N1 cases among dairy herds, as well as infections in some farm workers; in the case of the latter, poor sanitation around milking machines has been named as a key transmission factor. Milking a cow in Texas. Avian influenza is spreading among US cattle, most likely during milking. In fact, some 75% of recent disease outbreaks and epidemics can largely be traced to zoonotic spillovers to human populations – related to deforestation, poor regulation of domestic animal production, as well as poorly regulated wildlife markets and consumption, Jamal points out citing a widely held view amongst public health experts. Aims and practices of One Health Training farmers in judicious use of antibiotics, vaccines and surveillance of animals for unusual disease outbreaks are all important One Health practices. The overarching aim of One Health, according to WHO, is to “balance and optimize the health of people, animals and the environment… It involves veterinary, public health and environmental sectors.” One Health approaches most commonly involve practical efforts to improve: Animal and ecosystem surveillance for pathogens of risk to humans and not only for species protection; Community water, waste and sewage management to improve human hygiene and prevent the breeding of vector-borne diseases, from dengue to zika and malaria. Sustainable milk and meat production, including sanitation and management of waste. Poor waste management in concentrated pig farming was, for instance, named as one possible source for the 2009 eruption H1N1 (Swine flu). Animal use of antibiotics and other antimicrobial agents whose efficacy has been eroded by rampant veterinary overuse, leading to growing threats to human health from antimicrobial resistance (AMR). Forests: preventing rampant deforestation that drives rodents, insects and other wild animals and their pathogens into human communities – driving spread of dengue, Chagas, and more recently nipa virus; Deforestation fragments wild animal habitats, increasing pathogen contact and risks to humans. Wild animal breeding, trade, and consumption. The spread of the first SARS virus from bats to palm civets and then to humans via wild animal markets is well documented. A number of prominent scientists attribute the emergence of SARS-CoV2 to similar pathways – although others disagree. In Africa, the hunting and consumption of bushmeat (from reptiles to mammals) has been linked to the emergence of major diseases such as HIV and Ebola, as well as mpox – although bushmeat is also valued as an important protein source. Health and wildlife surveillance disconnect Arlette Dinde, Côte d’Ivoire researcher (second from right) describes the continuing health-wildlife research disconnect. Despite much debate in WHO pandemic talks about improving disease surveillance to identify emerging pathogen risks earlier – the very first link in the surveillance chain remains broken, noted Arlette Dinde a research associate at the Swiss Centre for Scientific Research in Côte d’Ivoire. Dinde recently led a 10-year, multi-country review of research of studies on wildlife in Côte d’Ivoire covering 2012-2022, including both the period of the West African Ebola epidemic (2014-2016) as well as COVID-19. The study identified a trend towards more wildlife research over that decade – but still little attention to the public health threats. “Research is still much more focused on biodiversity and conservation, and much less about the health and food security aspects,” Dinde said, noting that zoonoses and public health risks were mentioned in only about 22% of the research on wildlife and biodiversity identified. Conversely, “only about 5% of [public-health focused] research addressed aspects of wildlife disease surveillance,” she said. Not surprisingly then, government wildlife or farm sector planning doesn’t typically include the health sector, she found. She lamented the “lack of collaboration between the different sectors in the government, when we could have a great opportunity to push the wildlife sector into the public health system, and have a national One Health plan, around which we could coordinate.” A dangerous pathogen found in Mexico could ‘be in Geneva’ next Roche: a wild animal pathogen in Asia or Latin America can quickly be transported to Europe. PREZODE, an international One Health network is working with governments in 25 countries around the world, including projects to curb dangerous deforestation patterns, which drive more wild animals, rodents and insects into villages, towns and cities every year. Efforts include a pilot effort in Thailand for “reforestation by communities that can actually try to reduce diseases, and especially rodent borne diseases, which is generally a group of diseases that don’t receive enough attention,” said Benjamin Roche, co-founder of the international NGO. Similarly the group is trying to develop a “win-win strategy” in Mexico’s Yucatan province, a sensitive tropical area that is also one of the most deforested in the world, to improve biodiversity protection in ways that also reduce human exposure to zoonotic diseases. “I’s not just about biodiversity protection,” Roche underlined. “It’s also about education in some very remote rural communities, working closely with local NGOs in order to try to fit together real integrative prevention strategies in place.” It’s also about global health security, he underlined, in light of the speed at which emerging pathogens and outbreaks can travel: ”The Yucatan Penninsula is connected with Mexico by 10 flights a day, and Mexico City is 25 million people. So you can imagine that when you have a pathogen jumping from Yucatan to Mexico City – it is almost already in Geneva.” Changing norms around wildlife markets Most early, confirmed cases of SARS CoV2 were traced back to Wuhan’s Wholesale Seafood Market – although a definite animal ‘vector’ has never been established. Nowhere was that principle demonstrated better than in China during the SARS-CoV 2 pandemic and the rapid international transmission of COVID-19. Since that time, China has cracked down on wildlife markets, which were often patronized by more affluent groups which considered wild animal meat as a kind of “prestige” cuisine, noted Chloe Clifford Astbury, a researcher at the York University School of Public Health. China has also rolled back its former support for the commercial breeding of certain wildlife species, which may have played a role as intermediary hosts of SARS-CoV2, transmitting the virus to humans, particularly in the early days of the outbreak in Wuhan. “But wildlife is still used and traded for other uses, just not necessarily for consumption,” she added. In comparison, in central African countries like the DRC, wildlife, or bushmeat consumption is more widely a practice of lower income and rural communities “who depend on it as a source of protein, or as a source of income, for example, selling in the markets.” While there are laws on the books preventing hunting of certain species, on-the-ground convictions are relatively rare. Community involvement is key Community inclusion in One Health activities is critical. But Dinde, like Roche, stressed the importance of community involvement in development of government regulations – if One Health-related measures are to succeed. For instance, she said that she doesn’t support blanket bans on bushmeat consumption – noting that such decrees are widely ignored. And many African communities still rely on bushmeat as a “vital source of protein, she said. Following Côte d’Ivoire’s banning of bushmeat consumption during the 2014-16 West African Ebola epidemic, she led a paper evaluating its impacts, which found: “While fish and edible mushrooms seem to have filled related protein deficits in the households assessed… constraints in availability and utilization of these alternative sources build an inconsistent basis to fulfill the nutritional needs [of rural populations]. Such bans, therefore, needed to be accompanied by a stronger development of fish farming and livestock production to improve access to vital protein sources and insure that nutrition is not undermined. At the same time, communities need to be more sensitized to the risks that some bushmeat poses and how to minimize those – for instance by avoiding consumption of animals found dead in a forest – which may have perished due to disease. “Most of the time, communities will eat those animals [found dead in the forest] now,” she says, noting that there is little awareness of the risks involved. One Health: why should we tackle it in the pandemic agreement? Linking animal and human health surveillance is critical to pandemic prevention. Paradoxically, a clause regarding the “involvement of communities” in One Health remains a key disputed clause in the pandemic text, noted Jamal. And despite animal-borne diseases pose the leading pandemic risks of the future, some member states continue to argue that One Health doesn’t belong in the pandemic treaty at all, she added. “They ask ‘why should we tackle this in the Pandemic Instrument,” she said. “They say, why not just give pieces of One Health to WHO, to the WOAH [World Organization for Animal Health] to UNEP, to FAO, and , etc.. and on the national level, just leave them in their boxes?” One Health in draft Pandemic Agreement: Yellow text signals ‘convergence, but not agreement’. No agreement on community involvement. Historically, activities at country level, and globally, have “been quite siloed,” Astbury notes. “Both at the national and global level, there’s so much to be gained from intersectoral collaboration and so much loss when there’s really siloed ways of working,” she said. “Take surveillance, for example, there’s so much potential additional knowledge so much sharing is good practice that you can get through an integrated surveillance system – compared to a siloed one. “I know a lot of countries are struggling with implementing something like that. Historically, things have been quite siloed, and they are now trying to bring them together. “So coming together and thinking about trade offs and co-benefits is really important. And to do that, you can’t work in that kind of a siloed way.” Adds Roche: “An outbreak somewhere, even quite remote, can be a pandemic very quickly. So the vertical approach is not working any more. “Look at COVID-19, which was just a couple of cases in December, and it was a worldwide pandemic just four months later. It’s just an illustration of how quick and viral these things can be. It’s not like 20 years ago, we have a lot of small threats emerging all of the time. It means we have to change our approach.” Concluded Eric Comte, director of the Global Health Forum, which co-sponsored the event: “One Health is a bridge, a bridge between different scientific disciplines and a bridge between science and policy. There is no one single One Health solution, but stage by stage we can make progress.” Image Credits: Arend Kuester/Flickr, Flickr/M M, Josh Kelahan, PREZODE, PREZODE , PREZODE , WHA . Assistive Technology Report Brings More Transparency to Market 06/06/2024 Zuzanna Stawiska For many, access to assistive technology can enable independent everyday life. Only one in five of the people in need of hearing aids and prostheses worldwide can access them, according to a new report by ATscale, a global partnership for assistive technologies and the Clinton Health Access Initiative (CHAI). Assistive technology (AT) is any device and related systems that can help with everyday activities, improving or restoring the capabilities of a person’s body, ranging from eyeglasses, access ramps, prostheses or smartphones for functionalities such as the text-to-speech option. The report, issued on the first-ever Day for Assistive Technology, aims to make assistive technology markets more transparent and easier to navigate for the public sector and producers. The hope is that comprehensive information will facilitate the choice of quality products, especially for governments in low- and middle-income countries, and encourage companies to expand their reach to new regions of operation, explained Pascal Bijleveld, CEO of ATscale in an interview for Health Policy Watch. “It’s really about addressing one of the bottlenecks to access, which is the lack of transparency in the markets about what products are available, what are the price ranges, what’s the quality, and so on and so forth,” Bijleveld said. Many governments lack the capacity to analyse and understand each of the markets and may make sub-optimal product choices. It is also essential to raise awareness about the benefits of assistive technology and to start public and private initiatives to ensure more people, especially in low-income countries, can attain the AT they need. Large gap in access Getting a AT of need is often the key to a more independent, full life for people with disabilities, unlocking a possibility to live independently, meet with family and friends, study, or work. Globally, 2.5 billion people need at least one assistive product with the number expected to reach 3.5 billion by 2050 as the world population ages, WHO’s and UNICEF’s report shows. Even though 90% of people in need of an AT in high-income countries can access it, the number drops drastically to only 10% in low- and middle-income countries. There is a nine-to-one return on investment from providing AT, thanks to unlocked educational outcomes, better paid employment and lower longer-term healthcare costs, an ATscale study from 2022 highlights. The report systematically analyses markets for several most popular technologies: wheelchairs, glasses, augmentative communication, screen readers, and smartphones. Hearing aids, glasses and other assistive technologies can be prohibitively expensive. Taken for granted in wealthy countries, these simple technologies are out of reach for millions globally. It lists the product types available, describes market specifics and enumerates some of the most important features. For hearing aids, for example, approximately 20 million units are sold annually, with the main market drivers being the ageing population. When picking the right device, it’s important to consider its ability to manage background noise and acoustic loops, its resilience against mild shocks, dust or rain, volume control and overall design. Those and other features are tested by several control agencies; to help navigate the market, the report provides a comprehensive list of producers and certificates held by their devices. The report is only the first step, Bijleveld said and will be changed over the next couple of months into “a web-based platform that will be continuously updated”. Producers themselves will want to keep this interactive source of information up to date as a potential advertisement for their products and a guide to the overall market situation. Raising awareness about the benefits of ATs is on the top of ATscale’s agenda. ”People need to get the word out there,” Bijleveld stressed. Image Credits: CC. Global Leaders Appeal for More Resources Ahead of UN meeting on Antimicrobial Resistance 06/06/2024 Kerry Cullinan Drug-resistant bacteria have developed from years of over-prescription of antibiotics. With less than four months to the United Nations High-Level Meeting (HLM) on Antimicrobial Resistance (AMR), global leaders have proposed a variety of measures to address the growing threat of pathogens that are resistant to antibiotics. The recently published zero draft of the political declaration for the meeting aims to reduce global deaths caused by bacterial AMR by 10% by 2030 (using 2019 as the baseline). Mia Mottley, Prime Minister of Barbados and chairperson of the Global Leaders Group on AMR, called for “adequate, predictable and sustainable financing” to address the problem, including financing for research and development for new antibiotics and the implementation of national action plans on AMR, especially in low- and middle-income countries. “Fundamentally, we must focus on prevention across all sectors – clean water, safe and effective sanitation, food security, infection prevention and control in all settings,” Mottley told a lunchtime roundtable during last week’s World Health Assembly. Prime Minister of Barbados Mia Mottley, who chairs the Global Leaders Group on AMR “I believe that we should establish an independent panel to monitor and report on the science and the evidence to facilitate collaborative and coordinated action against AMR,” She also called for the quadripartite joint secretariat on AMR to be formalised and adequately resourced. This is made up of the World Health Organization (WHO), the UN Food and Agriculture Organisation (FAO), UN Environment Programme (UNEP), and the World Organisation for Animal Health (WOAH). The agricultural sector is responsible for the vast majority of antibiotic overuse, leading to drug resistance. Threatens to ‘unwind century of medical progress’ “In 2019, 1.3 million deaths resulted directly from bacterial AMR, more than two every minute,” WHO Director-General Dr Tedros Adhanom Ghebreyesus told the meeting. “AMR threatens to unwind the century of medical progress and also threatens animal health, global food production, food security, and the environment.” Dr Jean Kaseya, Director-General of Africa CDC, noted over one million deaths in Africa were associated with AMR and 250,000 caused by ARM. “Only 1.3% of our labs in Africa are able to perform bacterial resistance testing. It means this data that I’m sharing with you is an underrepresentation of the reality in Africa,” said Kaseya. Four years ago, the African Union Assembly established a task force to control AMR and recommended that all member states implement national action plans. “But less than 10% of a member states have national action plans that are fully funded and implemented,” he added. Kaseya appealed to The Global Fund to expand its mandate from HIV, TB, and malaria to include AMR. Professor Sally Davies, UK Special Envoy on AMR Professor Sally Davies, the UK Special Envoy on AMR and a member of the Global Leaders Group, called for the high-level meeting to “truly address the needs of the most vulnerable communities, offering clear support to low and middle-income countries” that carry the greatest burden of this antibiotic emergency and need fair and equitable access to antibiotics and diagnostics. Surviving AMR Vanessa Carter developed a drug-resistant infection after a car crash cost her an eye. South African Vanessa Carter, chair of WHO Taskforce of AMR Survivors, shared her nightmare of being unable to shake an infection after being seriously injured in a car crash in Johannesburg and losing her right eye. The infection turned out to be the drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA). Hospital patients, people with wounds, and those who have surgery and medical devices implanted in their bodies are particularly at risk of MRSA. Today, I was privileged to share my lived experience of #AMR at the #WHA77 & talk about the work we have already achieved with the @WHO Task Force of AMR Survivors since its inaugural meeting in October 2023 Patients, carers & survivors help to demonstrate the real-world impact… pic.twitter.com/k9onObOpm5 — Vanessa Carter 🇬🇧🇿🇦 (@_FaceSA) May 31, 2024 Carter, who spent a month in hospital, had a prosthetic eye inserted and a number of surgeries. “In my sixth year of surgeries, and my fourth prosthetic [eye], I went out shopping one day, I came back to the car and I felt moisture on my face. When I pulled down the rearview mirror, I saw this pus seeping out of the cheek of the prosthetic,” Carter told the roundtable meeting. Her doctor told her she needed emergency surgery, but two weeks’ later the infection came back again. “I was under the care of different types of specialists, an ENT surgeon, ophthalmologist, plastic surgeon, maxillofacial surgeon, each of them prescribing antibiotics during surgeries,” she added. After almost a year of continued infections, doctors removed the prosthetic eye and sent it for testing and it was found to be contaminated with MRSA. What followed was a long and harrowing process during which the infection got into Carter’s bones before she was finally cured. “I’ve been an advocate for the last 11 years and, most recently, we’ve established the WHO Task Force of AMR Survivors,” said Carter. “Our biggest objective is to bring the human impact. When policy makers and members of the public understand exactly what it is, we can we can empower them. One of the documents we have worked on is a strategic technical guidance document for meaningful patient involvement. I would encourage you to go take a look at it.” World Will Permanently Exceed 1.5°C Tipping Point Before 2030 – At Current Carbon Emissions Rate 05/06/2024 Elaine Ruth Fletcher World reaches record high for annual temperatures over past 12 months – as 1.5°C tipping point approaches. ‘Extortion level’ capital costs put renewables out of reach in most developing economies; fossil fuel companies rake in record profits; and world reels from record heat, freak floods and drought, says UN Secretary General. New climate data released Wednesday shows virtually all key global warming parameters, including land and sea temperatures at all time record high levels for May, as well as for the past year. There’s an 80% likelihood that in at least one of the next five years, the world will temporarily exceed the 1.5°C limit set by the 2015 Paris agreement, said the World Metereological Organization. And at current emissions rates, the world will permanently breach the 1.5° C limit before 2030, warned UN Secretary General Antonio Guterres in a stark message on climate change, coinciding with World Environment Day. “New data from leading climate scientists released today shows the remaining carbon budget to limit long term warning to 1.5 C is now around 200 billion tons – that is the maximum amount of carbon dioxide that the Earth’s atmosphere can take – if we are to have a fighting chance of staying within the limits,” Guterres said. His comments were based on projections released today by WMO and the European Union’s Copernicus climate observatory. “And the truth is, we are burning through the budget at reckless speed, spewing out around 40 billion tons of carbon dioxide a year,” he said urging people “to do the math.” “At this rate, the entire carbon budget will be passed before 2030,” he said in an address was delivered from New York City’s Museum of Natural History – to underline the point that the human species, like dinosaurs, faces a real extinction threat. World’s carbon ‘budget’ surpassed before 2030 UN Secretary General delivers a major address on climate Wednesday 5 June. To avoid permanently breaching the 1.5°C tipping point, global emissions need to fall by 9% every year until 2030, he said. “But they are heading in the wrong direction. Last year, they rose by 1%. “Almost 10 years since the Paris Agreement was adopted, the target of limiting long term global warming to 1.5 degrees Celsius is hanging by a thread. Meanwhile, the godfathers of climate chaos, the fossil fuel industry, rake in record profits supported by a system of trillions [of dollars] in taxpayer funded subsidies.” ‘Extortion-level’ capital costs put green energy out of reach in developing countries Hospital in Johannesburg, South Africa with solar panels: Investments in African renewables was a woeful 1% even as costs globally tumble. It is money that is driving the world to “climate hell”, the UN Secretary General said, calling for a broad overhaul of finance priorities amongst G20 and G7 countries, as well as in private banks and multilaterals. Investments in African renewables represent just 1% of the world’s installed PV solar capacity – while oil and gas profiteers rake the continent for fossil fuels, he noted, citing recent data from the International Energy Agency. “Extortion level capital costs are putting renewables virtually out of reach for most developing and emerging economies – astoundingly and despite the renewables boom of recent years,” Guterres declared. “Clean energy investments in developed developing and emerging economies outside of China have been stuck at the same levels since 2015. Last year, just 15% of new clean energy investment went to emerging markets and developing economies outside China, countries representing nearly two thirds of the world’s population. “And Africa was less than 1% of [PV solar] installations – despite its wealth of natural resources, and vast renewables potential.” All that is coming at a time when globally, clean energy investments reached a record high last year, with wind and solar power growing faster than any other electricity source in developed economies, he noted. Hottest month and year on record Record high sea temperatures are changing ocean and air currents, bleaching corals, threatening ice caps – all accelerating the approach of climate tipping points. May 2024 also was the hottest day in recorded history – marking 12 consecutive months of the hottest weather for the planet ever on record, Guterres noted, citing the fallout that is also being felt from Delhi to the Americas – in terms of record temperatures on the Indian subcontinent, and fierce, unpredictable storms and flooding in southern Brazil. The new WMO report, also released Wednesday, backs that up with detailed data on the unprecedented levels of temperature rise on land as well as on the seas. The WMO report was led by the UK Met Service. Further data on global warming trends was released by the European Union’s Copernicus Climate Service. Based on that data, the global average temperature for the last 12 months (June 2023 – May 2024) is the highest ever on record, at 1.63°C above the 1850–1900 pre-industrial average. And crossing 1.5°C is not merely a matter of crossing a political target, Guterres stressed. “Scientists have alerted us that temperatures rising higher would likely mean the collapse of the Greenland Ice Sheet and the West Antarctic Ice Sheet with catastrophic sea level rise,” he said, And not only that, but also the “destruction of tropical coral reef systems and livelihoods of 300 million people; the collapse of the Labrador Sea currents that would further disrupt weather patterns in Europe; and widespread permafrost melt that will release devastating levels of methane – one of the most potent heat trapping gasses.” Health effects increasingly evident – impacting the poorest and vulnerable Water shortage in Ethiopia. Droughts, flooding and heat waves all create acute health impacts, as well as exacerbating chronic diseases, like cardiovascular disease. Even today, as humankind pushes planetary boundaries to the brink- shattering global temperature records are being recorded around the world, he pointed out. “Already the brutal heatwave has baked Asia with record temperatures, shriveling crops, closing schools and killing people. Cities from New Delhi to Bamako to Mexico City are scorching. Here in the West severe storms have destroyed communities and lives. “We have seen drought and disaster declared across southern Africa and extreme rains flood the Arabian Peninsula, East Africa and Brazil. “And the mass global coral bleaching caused by unprecedented ocean temperatures – soaring past the worst predictions of scientists,” he said, noting that the cost of climate “chaos” could rise to at least $30 trillion by 2050.” And while the rich can huddle inside air conditioned bubbles, at least much of the time, those least responsible for the crisis bear its brunt, he noted. “Extreme events turbocharged by climate change are piling up – destroying lives, families’ economies and hammering health, wracking sustainable development, forcing people from their homes and rocking the foundations of peace and security as people are displaced and vital resources are depleted.” Appeal to G7 and G20 to fix broken financial system ‘Better, bigger and bolder’ commitments to green energy needed from multilateral development banks. To reverse current trends, Guterres called on world leaders, and particularly G7 leaders meeting nexxt week in Italy, as well as the G20, in Rio in November, to commit to ending coal production by 2030 and reduce oil and gas production by 60% – as compared to trillions in fossil fuel subsidies. The world’s leading economies also should: Set up a “high integrity” system for carbon taxes and markets; Relieve the debt burden in developing economies so that investment can flow into green forms of energy; Commit to finally filling the coffers of the Green Energy Fund, with the $100 billion in funds agreed to in previous Climate Conferences, for developing countries. He appealed to private financial institutions to stop funding coal, oil and gas projects – while the G7 and G20 countries should use their influence with multilateral development banks to make “better, bigger and bolder” commitments to green energy infrastructure. “The International Energy Agency reports that clean energy investments in developing and emerging economies beyond China need to reach up to $1.7 trillion a year by the early 2030s. “In short, we need a massive expansion of affordable problem to public and private finance to fuel ambitious new climate plans and deliver clean, affordable energy for all,” he said, pointing to the UN Summit of the Future planned for September “to push reform of the international financial architecture.” Meanwhile, private financial institutions should stop “”bankrolling fossil fuel destruction and start investing in a global renewable revolution,” while shareholders press for disclosure of engagements on fossil fuel multinationals – which have pressed on the gas, rather than releasing the pedal, investing a mere 2.5% in renewable projects, on average last year. Ban advertising of ‘unhealthy’ fossil fuels, as with tobacco Fossil fuels kill, like tobacco. Business and government leaders, moveover, need to confront disinformation and “greenwashing” by the fossil fuel industry, more aggressively. “Many governments restrict or prohibit advertising for products that are dangerous to human health like tobacco,” he pointed out. Some are now doing the same for fossil fuels. “I urge every country to ban advertising from fossil fuel companies. And I urge news media and tech companies to stop taking fossil fuel advertising. Embrace clean technologies Cycling in Fortaleza, Brazil – the city strengthened its active transport system, which reduces carbon emissions from motor vehicles. Meanwhile, he said, the general public can press on demand-side levers. “All of us can make a difference by embracing clean technology, phasing down fossil fuels in our own lives, and using our power as citizens to push for systemic change in the fight for a Livable Future. “People everywhere are far ahead of politicians. Make your voices and your choices count your friends. We do have a choice, creating tipping points for climate progress or gaining tipping points for climate disaster.” Image Credits: World Metereological Organization, Health Care Without Harm , WMO , Oxfam East Africa, WHO FCTC, City of Fortaleza. Strengthening Our Response to Malaria and Neglected Tropical Diseases in a Warming World 05/06/2024 Ibrahima Socé Fall & Michael Adelkunle Charles These children from Savai’i Island, Samoa, are protected by a mosquito net while they sleep. Climate change is perhaps the greatest threat to human health. In a warming world, with changing and unpredictable weather patterns, its effects are all around us. In 2022, Pakistan experienced the worst floods in the country’s history, placing much of the country under water and giving way to a fivefold increase in the country’s rate of malaria transmission. Earlier this year, Brazil declared a state of emergency as its national healthcare system buckled under the pressures of an outbreak of dengue, a neglected tropical disease (NTD) carried by mosquitoes. Cases continue to rise and the outbreak shows no sign of stopping. But Brazil is not alone. Over the past two decades, dengue cases have increased eightfold, with the mosquitoes that carry it thriving in areas where climate change has made temperatures higher and precipitation more abundant. Despite these daily reminders, there is much we do not understand about the impact climate change is exacting on malaria and NTDs, both of which disproportionately impact low-income countries (LICs). An ongoing effort to rid the world of these debilitating diseases by understanding the impacts of climate change isn’t just important – it’s imperative. Evidence gaps An unprecedented scoping review highlights significant gaps in evidence. It was conducted by the World Health Organization (WHO) Task Team on Climate Change, NTDs and Malaria, in partnership with Reaching the Last Mile, a portfolio of global health initiatives driven by the philanthropy of United Arab Emirates President Sheikh Mohamed bin Zayed Al Nahyan. Spanning 42,693 articles from the past decade, the review correlates climate fluctuations with changing disease patterns, confirming that changing temperature and rainfall patterns will shift the transmission windows and geographies of malaria, dengue and chikungunya. The research also reveals that, as our planet warms, the poorest and most vulnerable communities are poised to suffer even more. It also highlights that our research agenda is imbalanced, with studies historically focused on where disease burden is low and access to quality healthcare is high. This is not merely a health issue but a profound injustice that compounds vulnerabilities among those least equipped to bear them. Given the complex and nonlinear ways these diseases interact with changing climates, the importance of closing our gap in understanding is clear. As we already see with dengue in Brazil – and will continue to see in other areas for years to come – diseases are being transmitted faster and farther than before as vectors like mosquitoes expand to regions previously unexposed to these diseases. This could lead to new outbreaks in populations without any natural resistance or existing health infrastructure to manage such diseases. It’s only further complicated by increased displacement and migration as a result of a changing climate. Adaptation and mitigation Health officials speak to community members in Tana River County, Kenya, about the ongoing oral cholera vaccination campaign. Despite the clear risk, our understanding of how to mitigate or adapt to the impact of climate change on malaria and NTDs is limited. Adaptation and mitigation strategies were discussed in only a fraction of the scientific literature reviewed by the WHO Task Team. This needs to change. A new research agenda is crucial to inform evidence-based adaptation and mitigation strategies. In a world acutely aware of the effects of climate change, this all matters immensely if we are to preserve our gains and investments. As global citizens and stakeholders in global health – whether policymakers or researchers, NGOs, funders, or community leaders— we must adapt our strategies and responses not just to the diseases as we’ve known them, but to how they will evolve in a changing climate. This will require innovative approaches to our public health interventions as dynamic as the challenges they aim to counter. We must build resilient, climate-responsive health systems, surveillance programs and intervention strategies to mitigate against or adapt to the immediate-short-term and long-term effects of climate change on malaria and NTDs. We must ensure communities have the resources to respond to health threats in the context of real-time challenges and changing dynamics, like rising temperatures, extended rainy seasons or drought – particularly in the ‘last mile.’ This will require us to reimagine and invest in a new research agenda driven by scientists on the frontlines of this climate-vector-borne disease nexus aimed at protecting those most vulnerable to its impact. Stronger action on the ground We need a committed, global push for research that not only tracks disease trends but actively explores robust intervention strategies that consider the full spectrum of climate impacts. This includes a holistic approach to hazard assessment, driven by research that examines the links between hazards, vulnerability and exposure so we can more accurately project the potential effects of climate change on malaria and NTDs. The climate crisis will only continue to put strain and pressure on already fragile health systems, diverting precious resources from other budget lines, including malaria and NTDs. With more evidence, we can break this cycle and protect the resources needed for disease response. Last week, the World Health Assembly adopted the WHO’s 14th Global Programme of Work, which prioritises the climate-health nexus. Member states also adopted the strongest resolution yet on climate change and health. Now we need to see even stronger action on the ground. Let’s marshal our collective resources and ingenuity to ensure that our responses are as adaptable as the diseases we’re striving to overcome. The time to act is now. This new WHO paper is not just a summary of data; it’s a call to action. It’s a directive for all of us involved in the fight against malaria and NTDs to look beyond our current horizons and plan for a future where climate change reshapes the landscape of global health. For the sake of the millions at risk, we must heed this call and act swiftly and decisively. It’s no small challenge, but one that we can overcome together. Dr Ibrahima Socé Fall is the Director of WHO’s Global NTD Programme. Dr Michael Adelkunle Charles is CEO of the RBM Partnership to End Malaria. Image Credits: Yoshi Shimizu, Billy Miaron/ WHO. WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Zimbabwe Struggles With Rising Diabetes – And Lack of Data on Prevalence Amongst Children 07/06/2024 Jeffrey Moyo A health worker tests a patient for diabetes. Like most African countries, non-communicable (NCDs) diseases, including diabetes, is increasing in Zimbabwe. And children are increasingly among the cases that go undetected or treatment until severe symptoms emerge. HARARE, Zimbabwe – Ten-year-old Tadisa Sayi already contends with diabetes and when his blood sugar levels spike his mother, Naume Shereketo, endures the mood swings induced by his condition. Three years ago, Shereketo, a single mother of two, discovered the root cause of her son’s misery during a severe bout of illness. “It was in 2021. He was weak and vomiting. When I went to the hospital with him, doctors told me he was diabetic,” Shereketo told Health Policy Watch. “He always says: “Mama, I’m weak’, and some other time he is harsh,” said Shereketo. Shereketo, a vegetable vendor on the streets of Harare, faces ballooning costs to attend to her son’s special dietary needs. She struggles to provide the specific foods required for her son’s health. For Sayi, a grade four learner, fruit, vegetables, milk and high-fibre foods, have become a regular but costly part of his diet, costing his mother between $60 and $80 monthly. Shereketo is puzzled about her son’s diabetes. No one else is diabetic in her family or the boy’s paternal side. Dr Life Zambezi, the boy’s doctor, confirmed that Sayi had Type 1 diabetes, and said that this can be challenging to manage in young children due to limited support at the community level as well as the difficulty of maintaining strict insulin routines. Type 1 diabetes, which causes glucose (sugar) in one’s blood to become too high, happens when a person’s body cannot produce a hormone called insulin that controls blood glucose. Changes in diet also cause rise in Type 2 diabetes While Type 1 diabetes is generally the result of a genetic condition, children also are being increasingly affected by Type 2 diabetes, as a result of changing diets and lifestyles, according to the UN children’s agency, UNICEF. Type 2 diabetes typically develops as a result of sedentary lifestyles, obesity and unhealthy eating habits, Zambezi notes. While it’s on the rise in most African countries, and usually associated with adults, he’s seeing more such cases among children. “Of late, children are also getting Type 2 diabetes, mainly caused by the changes in lifestyle. There is a rise in poor eating habits among children. In most cases they eat processed and unhealthy food leading to childhood obesity and eventually type 2 diabetes,” said Zambezi. But diabetic children like Sayi are too often only diagnosed only when they have developed a severe crisis, such as a diabetic coma. “NCDs in children result from a combination of genetic, environmental and behavioural factors,” Health and Child Care Deputy Minister Dr John Mangwiro explained at the launch. “When a young child is diagnosed with a non-communicable disease, this implies long-term treatment.” Dr Life Zambezi says that the high cost of insulin has made life miserable for people with diabetes, many of who cannot afford the life-saving medication. Diabetes incidence in Zimbabwe soaring – although data remains spotty Approximately 537 million people worldwide are living with diabetes, according to the according to the International Diabetes Federation (IDF), an umbrella organisation of over 240 national diabetes associations in 160 countries and territories globally. That includes 422 million people worldwide suffer from type 2 diabetes, the majority living in low- and middle-income countries, according to WHO, of the disease that kills 1.5 million people every year. That includes approximately 106,400 adults in Zimbabwe living with diabetes Type 1 and 2, a prevalence of 1.5% in the adult population of about 7.1 million, according to the International Diabetes Federation (IDF), an umbrella organisation of national diabetes associations in 160 countries and territories. However, IDF’s local member, the Zimbabwe Diabetic Association, says that’s a woeful underestimate. It estimates that as many as 10 out of every 100 people in Zimbabwe’s population of 17 million had diabetes, including children, as of 2017. But many cases go undiagnosed until the child or adult in question becomes seriously ill. A 2014 meta-analysis also suggests diabetes incidence has grown exponentially. Prior to 1980, the prevalence of diabetes in Zimbabwe was just 0.44 %, while after 1980 the prevalence was 5.7 %, according to that systematic review. By 2018, prevalence was estimated at 8.5%, according to yet another study. As of 2016, Zimbabwe had the third highest estimated per-person cost of diabetes care in sub-Saharan Africa. Insulin’s exorbitant prices also cause many to miss out on essential medication, exacerbating their condition and long-term health risks, Zambezi said. Treatment at primary health care level is spotty Treatment in primary health clinics remains spotty, the studies also suggests. One small study comparing treatment in primary versus hospital facilities in Harare, the capital city, found that more patients treated at hospital outpatient clinics ahd received some form of diabetes self-management education (DSME), and had higher levels of diabetes knowledge, as compared to those treated in primary care facilities. At the same time, people who had consulted a dietician had the best levels of diabetes knowledge and self-care routines. “Dietitian-led interventions significantly improved both knowledge and practices, highlighting a need to scale up dietetic intervention, particularly in primary clinics where limited interventions occur,” concluded the July 2019 study led by a researchers at the University of Cape Town and the University of Zimbabwe’s Department of Community Medicine. “Though improvements have been made in self-management therapies, there seems to be a high prevalence of hospital admissions with relapse of symptoms in Zimbabwe. Relapse in diabetes predicts poor prognosis,” concluded another, 2021 study, led by the University of Zimbabwe’s Department of Nutrition. Recognizing those gaps, UNICEF in 2022 launched an initiative in five countries including Zimbabwe, to focus on NCD prevention, detection, treatment and support, particularly in children and young adults. As part of the grant, funded by the pharma firm, Eli Lilly, Zimbabwe’s Ministry of Health received $2.5 million to educate community health workers and increase support and understanding of various NCDs including diabetes in children. Late detection and poor management results in adult complications Diagnosed with diabetes 20 years ago, 30-year-old Tariro Chiripanyanga is now contending with end-stage kidney disease as a result of poor management of her diabetes. But until earlier detection and prompt treatment become more of the norm, many children will continue end up with severe complications in early adulthood, Zambezi observed. One such case is Tariro Chiripanyanga. The youngest of four siblings, Chiripanyanga was diagnosed with Type 1 diabetes at the age of 10. Today Chiripanyanga is now facing end-stage kidney disease, although she is only 30 years old. “I was still too young to understand what it meant or how it would affect my life, but that’s when my life changed forever,” Chiripanyanga told Health Policy Watch. Apart from living with diabetes since childhood, Chiripanyanga was diagnosed with kidney disease six years ago. She needs $30,000 for a kidney transplant, a financial burden neither she nor her family can bear. Chiripanyanga’s diabetes has already led to partial blindness, forcing her to drop out of university. “My life depends on peritoneal dialysis which costs $1,750 monthly,” Chiripanyanga said. “I depend on dialysis until I can get money for a transplant which costs an estimated $30,000 in India.” Image Credits: Muhidin Issa Michuzi, Jeffrey Moyo. One Health is a ‘One World’ Agenda, Even as Negotiators Wrangle Over Inclusion in WHO Pandemic Accord 06/06/2024 Elaine Ruth Fletcher ‘There is no one way to implement One Health solutions:’ Eric Comte, at podium with panelists describing country experiences: (left to right) Benjamin Roche, Chloe Astbury, Arlette Dinde and moderator, Nina Jamal. Is One Health really an agenda of only the Global North? Panelists at an event last week, hosted by the Geneva Graduate Institute’s Global Health Center, think otherwise. They talked about how developing countries are putting One Health principles into practice to head off future disease outbreaks. One Health is critical to future prevention of outbreaks and pandemics, and wider application of One Health principles should be a common agenda of both the global North and South – even if negotiators continue to wrangle over its inclusion in the still-unfinished World Health Organization (WHO) pandemic agreement. Those were key messages emerging from a dialogue co-sponsored by the Global Health Center (GHC) together with the Geneva Health Forum on the sidelines of last week’s World Health Assembly. At WHA, negotiators received a new mandate from member states to continue talks to conclude a pandemic accord by the 2025 WHA at the latest. The talks are set to resume in July. The Geneva Health Forum, convened by the University of Geneva and partners on the first three days of the 2024 World Health Assembly, brings together key global health scientists and policymakers with medical practitioners and other field actors. During the last frenzied weeks of negotiations just before WHA, the inclusion of references to One Health principles in Article 5 of the draft text spurred opposition from some low- and middle income countries (LMICs) as well as some civil society organizations. In late May, 68 CSOs called on negotiators to ‘Reject One Health Instrument’ in the pandemic agreement. They argued that One Health provisions intended to boost pathogen surveillance and pandemic prevention could also enable developed countries to erect new trade barriers and data demands on developing countries, and impose more costly pandemic preventive measures which poorer countries could not afford to implement. Over 120 experts and civil society proponents shot back with an open letter of their own. They asserted that better recognition of One Health principles and practices is critical to prevent more deadly spillover of zoonotic diseases into human populations, which could cause the next pandemic, as well as more locally disease outbreaks that typically kill people in LMICs first of all. Many One Health projects already taking place in Africa, South-East Asia Nina Jamal, Four Paws International. “Is One Health really a global North agenda?” asked moderator Nina Jamal, International Head of Pandemics and Campaign Strategies at Four Paws International, which also co-sponsored the event. The soft-spoken Jamal, a Lebanese-Austrian with a wealth of experience straddling such ‘North’ and ‘South’ polarities, has become one of the leading advocates One Health in the pandemic agreement, patiently sitting through countless late-night sessions, and speaking one-on-one with delegates about their views and concerns over more than two years of negotiations. “The perception is that One Health involves a set of obligations imposed by high income countries on low-income ones. But is all the knowledge and expertise on One Health in the global North?” asked Jamal. At the GHC event, researchers working in countries as diverse as the Cote d’Ivoire, Guinea, Mexico, China and the Democratic Republic of Congo, described how they they are putting One Health principles into practice to promote better animal surveillance, reduced deforestation, and improved practices around wildlife management in food markets and trade – and document related health benefits. Most recent outbreaks linked to lack of ‘One Health’ measures Live chickens await slaughter at a traditional market in Lanzhou, China. Along with mammals, live poultry also harbor pathogens that can infect humans, in instances such as the H5N1 outbreak of avian influenza of the late 1990s. Most recent outbreaks of disease that have hit developing countries harder than developed ones are somehow related to an overall dearth of One Health measures that needs to be addressed, the experts asserted. Examples range from Ebola, Lassa fever and mpox in Africa, to SARS and Nipa virus in Asia, and expanding circles of dengue virus, Chagas disease, in Latin America. Countries in the global North are not immune either. That was evident in the 2009 H1N1 [swine flu] pandemic, that first appeared in Mexico and the United States, and ultimately infected up to 80 million people. More recently the US has seen a surge in H5N1 cases among dairy herds, as well as infections in some farm workers; in the case of the latter, poor sanitation around milking machines has been named as a key transmission factor. Milking a cow in Texas. Avian influenza is spreading among US cattle, most likely during milking. In fact, some 75% of recent disease outbreaks and epidemics can largely be traced to zoonotic spillovers to human populations – related to deforestation, poor regulation of domestic animal production, as well as poorly regulated wildlife markets and consumption, Jamal points out citing a widely held view amongst public health experts. Aims and practices of One Health Training farmers in judicious use of antibiotics, vaccines and surveillance of animals for unusual disease outbreaks are all important One Health practices. The overarching aim of One Health, according to WHO, is to “balance and optimize the health of people, animals and the environment… It involves veterinary, public health and environmental sectors.” One Health approaches most commonly involve practical efforts to improve: Animal and ecosystem surveillance for pathogens of risk to humans and not only for species protection; Community water, waste and sewage management to improve human hygiene and prevent the breeding of vector-borne diseases, from dengue to zika and malaria. Sustainable milk and meat production, including sanitation and management of waste. Poor waste management in concentrated pig farming was, for instance, named as one possible source for the 2009 eruption H1N1 (Swine flu). Animal use of antibiotics and other antimicrobial agents whose efficacy has been eroded by rampant veterinary overuse, leading to growing threats to human health from antimicrobial resistance (AMR). Forests: preventing rampant deforestation that drives rodents, insects and other wild animals and their pathogens into human communities – driving spread of dengue, Chagas, and more recently nipa virus; Deforestation fragments wild animal habitats, increasing pathogen contact and risks to humans. Wild animal breeding, trade, and consumption. The spread of the first SARS virus from bats to palm civets and then to humans via wild animal markets is well documented. A number of prominent scientists attribute the emergence of SARS-CoV2 to similar pathways – although others disagree. In Africa, the hunting and consumption of bushmeat (from reptiles to mammals) has been linked to the emergence of major diseases such as HIV and Ebola, as well as mpox – although bushmeat is also valued as an important protein source. Health and wildlife surveillance disconnect Arlette Dinde, Côte d’Ivoire researcher (second from right) describes the continuing health-wildlife research disconnect. Despite much debate in WHO pandemic talks about improving disease surveillance to identify emerging pathogen risks earlier – the very first link in the surveillance chain remains broken, noted Arlette Dinde a research associate at the Swiss Centre for Scientific Research in Côte d’Ivoire. Dinde recently led a 10-year, multi-country review of research of studies on wildlife in Côte d’Ivoire covering 2012-2022, including both the period of the West African Ebola epidemic (2014-2016) as well as COVID-19. The study identified a trend towards more wildlife research over that decade – but still little attention to the public health threats. “Research is still much more focused on biodiversity and conservation, and much less about the health and food security aspects,” Dinde said, noting that zoonoses and public health risks were mentioned in only about 22% of the research on wildlife and biodiversity identified. Conversely, “only about 5% of [public-health focused] research addressed aspects of wildlife disease surveillance,” she said. Not surprisingly then, government wildlife or farm sector planning doesn’t typically include the health sector, she found. She lamented the “lack of collaboration between the different sectors in the government, when we could have a great opportunity to push the wildlife sector into the public health system, and have a national One Health plan, around which we could coordinate.” A dangerous pathogen found in Mexico could ‘be in Geneva’ next Roche: a wild animal pathogen in Asia or Latin America can quickly be transported to Europe. PREZODE, an international One Health network is working with governments in 25 countries around the world, including projects to curb dangerous deforestation patterns, which drive more wild animals, rodents and insects into villages, towns and cities every year. Efforts include a pilot effort in Thailand for “reforestation by communities that can actually try to reduce diseases, and especially rodent borne diseases, which is generally a group of diseases that don’t receive enough attention,” said Benjamin Roche, co-founder of the international NGO. Similarly the group is trying to develop a “win-win strategy” in Mexico’s Yucatan province, a sensitive tropical area that is also one of the most deforested in the world, to improve biodiversity protection in ways that also reduce human exposure to zoonotic diseases. “I’s not just about biodiversity protection,” Roche underlined. “It’s also about education in some very remote rural communities, working closely with local NGOs in order to try to fit together real integrative prevention strategies in place.” It’s also about global health security, he underlined, in light of the speed at which emerging pathogens and outbreaks can travel: ”The Yucatan Penninsula is connected with Mexico by 10 flights a day, and Mexico City is 25 million people. So you can imagine that when you have a pathogen jumping from Yucatan to Mexico City – it is almost already in Geneva.” Changing norms around wildlife markets Most early, confirmed cases of SARS CoV2 were traced back to Wuhan’s Wholesale Seafood Market – although a definite animal ‘vector’ has never been established. Nowhere was that principle demonstrated better than in China during the SARS-CoV 2 pandemic and the rapid international transmission of COVID-19. Since that time, China has cracked down on wildlife markets, which were often patronized by more affluent groups which considered wild animal meat as a kind of “prestige” cuisine, noted Chloe Clifford Astbury, a researcher at the York University School of Public Health. China has also rolled back its former support for the commercial breeding of certain wildlife species, which may have played a role as intermediary hosts of SARS-CoV2, transmitting the virus to humans, particularly in the early days of the outbreak in Wuhan. “But wildlife is still used and traded for other uses, just not necessarily for consumption,” she added. In comparison, in central African countries like the DRC, wildlife, or bushmeat consumption is more widely a practice of lower income and rural communities “who depend on it as a source of protein, or as a source of income, for example, selling in the markets.” While there are laws on the books preventing hunting of certain species, on-the-ground convictions are relatively rare. Community involvement is key Community inclusion in One Health activities is critical. But Dinde, like Roche, stressed the importance of community involvement in development of government regulations – if One Health-related measures are to succeed. For instance, she said that she doesn’t support blanket bans on bushmeat consumption – noting that such decrees are widely ignored. And many African communities still rely on bushmeat as a “vital source of protein, she said. Following Côte d’Ivoire’s banning of bushmeat consumption during the 2014-16 West African Ebola epidemic, she led a paper evaluating its impacts, which found: “While fish and edible mushrooms seem to have filled related protein deficits in the households assessed… constraints in availability and utilization of these alternative sources build an inconsistent basis to fulfill the nutritional needs [of rural populations]. Such bans, therefore, needed to be accompanied by a stronger development of fish farming and livestock production to improve access to vital protein sources and insure that nutrition is not undermined. At the same time, communities need to be more sensitized to the risks that some bushmeat poses and how to minimize those – for instance by avoiding consumption of animals found dead in a forest – which may have perished due to disease. “Most of the time, communities will eat those animals [found dead in the forest] now,” she says, noting that there is little awareness of the risks involved. One Health: why should we tackle it in the pandemic agreement? Linking animal and human health surveillance is critical to pandemic prevention. Paradoxically, a clause regarding the “involvement of communities” in One Health remains a key disputed clause in the pandemic text, noted Jamal. And despite animal-borne diseases pose the leading pandemic risks of the future, some member states continue to argue that One Health doesn’t belong in the pandemic treaty at all, she added. “They ask ‘why should we tackle this in the Pandemic Instrument,” she said. “They say, why not just give pieces of One Health to WHO, to the WOAH [World Organization for Animal Health] to UNEP, to FAO, and , etc.. and on the national level, just leave them in their boxes?” One Health in draft Pandemic Agreement: Yellow text signals ‘convergence, but not agreement’. No agreement on community involvement. Historically, activities at country level, and globally, have “been quite siloed,” Astbury notes. “Both at the national and global level, there’s so much to be gained from intersectoral collaboration and so much loss when there’s really siloed ways of working,” she said. “Take surveillance, for example, there’s so much potential additional knowledge so much sharing is good practice that you can get through an integrated surveillance system – compared to a siloed one. “I know a lot of countries are struggling with implementing something like that. Historically, things have been quite siloed, and they are now trying to bring them together. “So coming together and thinking about trade offs and co-benefits is really important. And to do that, you can’t work in that kind of a siloed way.” Adds Roche: “An outbreak somewhere, even quite remote, can be a pandemic very quickly. So the vertical approach is not working any more. “Look at COVID-19, which was just a couple of cases in December, and it was a worldwide pandemic just four months later. It’s just an illustration of how quick and viral these things can be. It’s not like 20 years ago, we have a lot of small threats emerging all of the time. It means we have to change our approach.” Concluded Eric Comte, director of the Global Health Forum, which co-sponsored the event: “One Health is a bridge, a bridge between different scientific disciplines and a bridge between science and policy. There is no one single One Health solution, but stage by stage we can make progress.” Image Credits: Arend Kuester/Flickr, Flickr/M M, Josh Kelahan, PREZODE, PREZODE , PREZODE , WHA . Assistive Technology Report Brings More Transparency to Market 06/06/2024 Zuzanna Stawiska For many, access to assistive technology can enable independent everyday life. Only one in five of the people in need of hearing aids and prostheses worldwide can access them, according to a new report by ATscale, a global partnership for assistive technologies and the Clinton Health Access Initiative (CHAI). Assistive technology (AT) is any device and related systems that can help with everyday activities, improving or restoring the capabilities of a person’s body, ranging from eyeglasses, access ramps, prostheses or smartphones for functionalities such as the text-to-speech option. The report, issued on the first-ever Day for Assistive Technology, aims to make assistive technology markets more transparent and easier to navigate for the public sector and producers. The hope is that comprehensive information will facilitate the choice of quality products, especially for governments in low- and middle-income countries, and encourage companies to expand their reach to new regions of operation, explained Pascal Bijleveld, CEO of ATscale in an interview for Health Policy Watch. “It’s really about addressing one of the bottlenecks to access, which is the lack of transparency in the markets about what products are available, what are the price ranges, what’s the quality, and so on and so forth,” Bijleveld said. Many governments lack the capacity to analyse and understand each of the markets and may make sub-optimal product choices. It is also essential to raise awareness about the benefits of assistive technology and to start public and private initiatives to ensure more people, especially in low-income countries, can attain the AT they need. Large gap in access Getting a AT of need is often the key to a more independent, full life for people with disabilities, unlocking a possibility to live independently, meet with family and friends, study, or work. Globally, 2.5 billion people need at least one assistive product with the number expected to reach 3.5 billion by 2050 as the world population ages, WHO’s and UNICEF’s report shows. Even though 90% of people in need of an AT in high-income countries can access it, the number drops drastically to only 10% in low- and middle-income countries. There is a nine-to-one return on investment from providing AT, thanks to unlocked educational outcomes, better paid employment and lower longer-term healthcare costs, an ATscale study from 2022 highlights. The report systematically analyses markets for several most popular technologies: wheelchairs, glasses, augmentative communication, screen readers, and smartphones. Hearing aids, glasses and other assistive technologies can be prohibitively expensive. Taken for granted in wealthy countries, these simple technologies are out of reach for millions globally. It lists the product types available, describes market specifics and enumerates some of the most important features. For hearing aids, for example, approximately 20 million units are sold annually, with the main market drivers being the ageing population. When picking the right device, it’s important to consider its ability to manage background noise and acoustic loops, its resilience against mild shocks, dust or rain, volume control and overall design. Those and other features are tested by several control agencies; to help navigate the market, the report provides a comprehensive list of producers and certificates held by their devices. The report is only the first step, Bijleveld said and will be changed over the next couple of months into “a web-based platform that will be continuously updated”. Producers themselves will want to keep this interactive source of information up to date as a potential advertisement for their products and a guide to the overall market situation. Raising awareness about the benefits of ATs is on the top of ATscale’s agenda. ”People need to get the word out there,” Bijleveld stressed. Image Credits: CC. Global Leaders Appeal for More Resources Ahead of UN meeting on Antimicrobial Resistance 06/06/2024 Kerry Cullinan Drug-resistant bacteria have developed from years of over-prescription of antibiotics. With less than four months to the United Nations High-Level Meeting (HLM) on Antimicrobial Resistance (AMR), global leaders have proposed a variety of measures to address the growing threat of pathogens that are resistant to antibiotics. The recently published zero draft of the political declaration for the meeting aims to reduce global deaths caused by bacterial AMR by 10% by 2030 (using 2019 as the baseline). Mia Mottley, Prime Minister of Barbados and chairperson of the Global Leaders Group on AMR, called for “adequate, predictable and sustainable financing” to address the problem, including financing for research and development for new antibiotics and the implementation of national action plans on AMR, especially in low- and middle-income countries. “Fundamentally, we must focus on prevention across all sectors – clean water, safe and effective sanitation, food security, infection prevention and control in all settings,” Mottley told a lunchtime roundtable during last week’s World Health Assembly. Prime Minister of Barbados Mia Mottley, who chairs the Global Leaders Group on AMR “I believe that we should establish an independent panel to monitor and report on the science and the evidence to facilitate collaborative and coordinated action against AMR,” She also called for the quadripartite joint secretariat on AMR to be formalised and adequately resourced. This is made up of the World Health Organization (WHO), the UN Food and Agriculture Organisation (FAO), UN Environment Programme (UNEP), and the World Organisation for Animal Health (WOAH). The agricultural sector is responsible for the vast majority of antibiotic overuse, leading to drug resistance. Threatens to ‘unwind century of medical progress’ “In 2019, 1.3 million deaths resulted directly from bacterial AMR, more than two every minute,” WHO Director-General Dr Tedros Adhanom Ghebreyesus told the meeting. “AMR threatens to unwind the century of medical progress and also threatens animal health, global food production, food security, and the environment.” Dr Jean Kaseya, Director-General of Africa CDC, noted over one million deaths in Africa were associated with AMR and 250,000 caused by ARM. “Only 1.3% of our labs in Africa are able to perform bacterial resistance testing. It means this data that I’m sharing with you is an underrepresentation of the reality in Africa,” said Kaseya. Four years ago, the African Union Assembly established a task force to control AMR and recommended that all member states implement national action plans. “But less than 10% of a member states have national action plans that are fully funded and implemented,” he added. Kaseya appealed to The Global Fund to expand its mandate from HIV, TB, and malaria to include AMR. Professor Sally Davies, UK Special Envoy on AMR Professor Sally Davies, the UK Special Envoy on AMR and a member of the Global Leaders Group, called for the high-level meeting to “truly address the needs of the most vulnerable communities, offering clear support to low and middle-income countries” that carry the greatest burden of this antibiotic emergency and need fair and equitable access to antibiotics and diagnostics. Surviving AMR Vanessa Carter developed a drug-resistant infection after a car crash cost her an eye. South African Vanessa Carter, chair of WHO Taskforce of AMR Survivors, shared her nightmare of being unable to shake an infection after being seriously injured in a car crash in Johannesburg and losing her right eye. The infection turned out to be the drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA). Hospital patients, people with wounds, and those who have surgery and medical devices implanted in their bodies are particularly at risk of MRSA. Today, I was privileged to share my lived experience of #AMR at the #WHA77 & talk about the work we have already achieved with the @WHO Task Force of AMR Survivors since its inaugural meeting in October 2023 Patients, carers & survivors help to demonstrate the real-world impact… pic.twitter.com/k9onObOpm5 — Vanessa Carter 🇬🇧🇿🇦 (@_FaceSA) May 31, 2024 Carter, who spent a month in hospital, had a prosthetic eye inserted and a number of surgeries. “In my sixth year of surgeries, and my fourth prosthetic [eye], I went out shopping one day, I came back to the car and I felt moisture on my face. When I pulled down the rearview mirror, I saw this pus seeping out of the cheek of the prosthetic,” Carter told the roundtable meeting. Her doctor told her she needed emergency surgery, but two weeks’ later the infection came back again. “I was under the care of different types of specialists, an ENT surgeon, ophthalmologist, plastic surgeon, maxillofacial surgeon, each of them prescribing antibiotics during surgeries,” she added. After almost a year of continued infections, doctors removed the prosthetic eye and sent it for testing and it was found to be contaminated with MRSA. What followed was a long and harrowing process during which the infection got into Carter’s bones before she was finally cured. “I’ve been an advocate for the last 11 years and, most recently, we’ve established the WHO Task Force of AMR Survivors,” said Carter. “Our biggest objective is to bring the human impact. When policy makers and members of the public understand exactly what it is, we can we can empower them. One of the documents we have worked on is a strategic technical guidance document for meaningful patient involvement. I would encourage you to go take a look at it.” World Will Permanently Exceed 1.5°C Tipping Point Before 2030 – At Current Carbon Emissions Rate 05/06/2024 Elaine Ruth Fletcher World reaches record high for annual temperatures over past 12 months – as 1.5°C tipping point approaches. ‘Extortion level’ capital costs put renewables out of reach in most developing economies; fossil fuel companies rake in record profits; and world reels from record heat, freak floods and drought, says UN Secretary General. New climate data released Wednesday shows virtually all key global warming parameters, including land and sea temperatures at all time record high levels for May, as well as for the past year. There’s an 80% likelihood that in at least one of the next five years, the world will temporarily exceed the 1.5°C limit set by the 2015 Paris agreement, said the World Metereological Organization. And at current emissions rates, the world will permanently breach the 1.5° C limit before 2030, warned UN Secretary General Antonio Guterres in a stark message on climate change, coinciding with World Environment Day. “New data from leading climate scientists released today shows the remaining carbon budget to limit long term warning to 1.5 C is now around 200 billion tons – that is the maximum amount of carbon dioxide that the Earth’s atmosphere can take – if we are to have a fighting chance of staying within the limits,” Guterres said. His comments were based on projections released today by WMO and the European Union’s Copernicus climate observatory. “And the truth is, we are burning through the budget at reckless speed, spewing out around 40 billion tons of carbon dioxide a year,” he said urging people “to do the math.” “At this rate, the entire carbon budget will be passed before 2030,” he said in an address was delivered from New York City’s Museum of Natural History – to underline the point that the human species, like dinosaurs, faces a real extinction threat. World’s carbon ‘budget’ surpassed before 2030 UN Secretary General delivers a major address on climate Wednesday 5 June. To avoid permanently breaching the 1.5°C tipping point, global emissions need to fall by 9% every year until 2030, he said. “But they are heading in the wrong direction. Last year, they rose by 1%. “Almost 10 years since the Paris Agreement was adopted, the target of limiting long term global warming to 1.5 degrees Celsius is hanging by a thread. Meanwhile, the godfathers of climate chaos, the fossil fuel industry, rake in record profits supported by a system of trillions [of dollars] in taxpayer funded subsidies.” ‘Extortion-level’ capital costs put green energy out of reach in developing countries Hospital in Johannesburg, South Africa with solar panels: Investments in African renewables was a woeful 1% even as costs globally tumble. It is money that is driving the world to “climate hell”, the UN Secretary General said, calling for a broad overhaul of finance priorities amongst G20 and G7 countries, as well as in private banks and multilaterals. Investments in African renewables represent just 1% of the world’s installed PV solar capacity – while oil and gas profiteers rake the continent for fossil fuels, he noted, citing recent data from the International Energy Agency. “Extortion level capital costs are putting renewables virtually out of reach for most developing and emerging economies – astoundingly and despite the renewables boom of recent years,” Guterres declared. “Clean energy investments in developed developing and emerging economies outside of China have been stuck at the same levels since 2015. Last year, just 15% of new clean energy investment went to emerging markets and developing economies outside China, countries representing nearly two thirds of the world’s population. “And Africa was less than 1% of [PV solar] installations – despite its wealth of natural resources, and vast renewables potential.” All that is coming at a time when globally, clean energy investments reached a record high last year, with wind and solar power growing faster than any other electricity source in developed economies, he noted. Hottest month and year on record Record high sea temperatures are changing ocean and air currents, bleaching corals, threatening ice caps – all accelerating the approach of climate tipping points. May 2024 also was the hottest day in recorded history – marking 12 consecutive months of the hottest weather for the planet ever on record, Guterres noted, citing the fallout that is also being felt from Delhi to the Americas – in terms of record temperatures on the Indian subcontinent, and fierce, unpredictable storms and flooding in southern Brazil. The new WMO report, also released Wednesday, backs that up with detailed data on the unprecedented levels of temperature rise on land as well as on the seas. The WMO report was led by the UK Met Service. Further data on global warming trends was released by the European Union’s Copernicus Climate Service. Based on that data, the global average temperature for the last 12 months (June 2023 – May 2024) is the highest ever on record, at 1.63°C above the 1850–1900 pre-industrial average. And crossing 1.5°C is not merely a matter of crossing a political target, Guterres stressed. “Scientists have alerted us that temperatures rising higher would likely mean the collapse of the Greenland Ice Sheet and the West Antarctic Ice Sheet with catastrophic sea level rise,” he said, And not only that, but also the “destruction of tropical coral reef systems and livelihoods of 300 million people; the collapse of the Labrador Sea currents that would further disrupt weather patterns in Europe; and widespread permafrost melt that will release devastating levels of methane – one of the most potent heat trapping gasses.” Health effects increasingly evident – impacting the poorest and vulnerable Water shortage in Ethiopia. Droughts, flooding and heat waves all create acute health impacts, as well as exacerbating chronic diseases, like cardiovascular disease. Even today, as humankind pushes planetary boundaries to the brink- shattering global temperature records are being recorded around the world, he pointed out. “Already the brutal heatwave has baked Asia with record temperatures, shriveling crops, closing schools and killing people. Cities from New Delhi to Bamako to Mexico City are scorching. Here in the West severe storms have destroyed communities and lives. “We have seen drought and disaster declared across southern Africa and extreme rains flood the Arabian Peninsula, East Africa and Brazil. “And the mass global coral bleaching caused by unprecedented ocean temperatures – soaring past the worst predictions of scientists,” he said, noting that the cost of climate “chaos” could rise to at least $30 trillion by 2050.” And while the rich can huddle inside air conditioned bubbles, at least much of the time, those least responsible for the crisis bear its brunt, he noted. “Extreme events turbocharged by climate change are piling up – destroying lives, families’ economies and hammering health, wracking sustainable development, forcing people from their homes and rocking the foundations of peace and security as people are displaced and vital resources are depleted.” Appeal to G7 and G20 to fix broken financial system ‘Better, bigger and bolder’ commitments to green energy needed from multilateral development banks. To reverse current trends, Guterres called on world leaders, and particularly G7 leaders meeting nexxt week in Italy, as well as the G20, in Rio in November, to commit to ending coal production by 2030 and reduce oil and gas production by 60% – as compared to trillions in fossil fuel subsidies. The world’s leading economies also should: Set up a “high integrity” system for carbon taxes and markets; Relieve the debt burden in developing economies so that investment can flow into green forms of energy; Commit to finally filling the coffers of the Green Energy Fund, with the $100 billion in funds agreed to in previous Climate Conferences, for developing countries. He appealed to private financial institutions to stop funding coal, oil and gas projects – while the G7 and G20 countries should use their influence with multilateral development banks to make “better, bigger and bolder” commitments to green energy infrastructure. “The International Energy Agency reports that clean energy investments in developing and emerging economies beyond China need to reach up to $1.7 trillion a year by the early 2030s. “In short, we need a massive expansion of affordable problem to public and private finance to fuel ambitious new climate plans and deliver clean, affordable energy for all,” he said, pointing to the UN Summit of the Future planned for September “to push reform of the international financial architecture.” Meanwhile, private financial institutions should stop “”bankrolling fossil fuel destruction and start investing in a global renewable revolution,” while shareholders press for disclosure of engagements on fossil fuel multinationals – which have pressed on the gas, rather than releasing the pedal, investing a mere 2.5% in renewable projects, on average last year. Ban advertising of ‘unhealthy’ fossil fuels, as with tobacco Fossil fuels kill, like tobacco. Business and government leaders, moveover, need to confront disinformation and “greenwashing” by the fossil fuel industry, more aggressively. “Many governments restrict or prohibit advertising for products that are dangerous to human health like tobacco,” he pointed out. Some are now doing the same for fossil fuels. “I urge every country to ban advertising from fossil fuel companies. And I urge news media and tech companies to stop taking fossil fuel advertising. Embrace clean technologies Cycling in Fortaleza, Brazil – the city strengthened its active transport system, which reduces carbon emissions from motor vehicles. Meanwhile, he said, the general public can press on demand-side levers. “All of us can make a difference by embracing clean technology, phasing down fossil fuels in our own lives, and using our power as citizens to push for systemic change in the fight for a Livable Future. “People everywhere are far ahead of politicians. Make your voices and your choices count your friends. We do have a choice, creating tipping points for climate progress or gaining tipping points for climate disaster.” Image Credits: World Metereological Organization, Health Care Without Harm , WMO , Oxfam East Africa, WHO FCTC, City of Fortaleza. Strengthening Our Response to Malaria and Neglected Tropical Diseases in a Warming World 05/06/2024 Ibrahima Socé Fall & Michael Adelkunle Charles These children from Savai’i Island, Samoa, are protected by a mosquito net while they sleep. Climate change is perhaps the greatest threat to human health. In a warming world, with changing and unpredictable weather patterns, its effects are all around us. In 2022, Pakistan experienced the worst floods in the country’s history, placing much of the country under water and giving way to a fivefold increase in the country’s rate of malaria transmission. Earlier this year, Brazil declared a state of emergency as its national healthcare system buckled under the pressures of an outbreak of dengue, a neglected tropical disease (NTD) carried by mosquitoes. Cases continue to rise and the outbreak shows no sign of stopping. But Brazil is not alone. Over the past two decades, dengue cases have increased eightfold, with the mosquitoes that carry it thriving in areas where climate change has made temperatures higher and precipitation more abundant. Despite these daily reminders, there is much we do not understand about the impact climate change is exacting on malaria and NTDs, both of which disproportionately impact low-income countries (LICs). An ongoing effort to rid the world of these debilitating diseases by understanding the impacts of climate change isn’t just important – it’s imperative. Evidence gaps An unprecedented scoping review highlights significant gaps in evidence. It was conducted by the World Health Organization (WHO) Task Team on Climate Change, NTDs and Malaria, in partnership with Reaching the Last Mile, a portfolio of global health initiatives driven by the philanthropy of United Arab Emirates President Sheikh Mohamed bin Zayed Al Nahyan. Spanning 42,693 articles from the past decade, the review correlates climate fluctuations with changing disease patterns, confirming that changing temperature and rainfall patterns will shift the transmission windows and geographies of malaria, dengue and chikungunya. The research also reveals that, as our planet warms, the poorest and most vulnerable communities are poised to suffer even more. It also highlights that our research agenda is imbalanced, with studies historically focused on where disease burden is low and access to quality healthcare is high. This is not merely a health issue but a profound injustice that compounds vulnerabilities among those least equipped to bear them. Given the complex and nonlinear ways these diseases interact with changing climates, the importance of closing our gap in understanding is clear. As we already see with dengue in Brazil – and will continue to see in other areas for years to come – diseases are being transmitted faster and farther than before as vectors like mosquitoes expand to regions previously unexposed to these diseases. This could lead to new outbreaks in populations without any natural resistance or existing health infrastructure to manage such diseases. It’s only further complicated by increased displacement and migration as a result of a changing climate. Adaptation and mitigation Health officials speak to community members in Tana River County, Kenya, about the ongoing oral cholera vaccination campaign. Despite the clear risk, our understanding of how to mitigate or adapt to the impact of climate change on malaria and NTDs is limited. Adaptation and mitigation strategies were discussed in only a fraction of the scientific literature reviewed by the WHO Task Team. This needs to change. A new research agenda is crucial to inform evidence-based adaptation and mitigation strategies. In a world acutely aware of the effects of climate change, this all matters immensely if we are to preserve our gains and investments. As global citizens and stakeholders in global health – whether policymakers or researchers, NGOs, funders, or community leaders— we must adapt our strategies and responses not just to the diseases as we’ve known them, but to how they will evolve in a changing climate. This will require innovative approaches to our public health interventions as dynamic as the challenges they aim to counter. We must build resilient, climate-responsive health systems, surveillance programs and intervention strategies to mitigate against or adapt to the immediate-short-term and long-term effects of climate change on malaria and NTDs. We must ensure communities have the resources to respond to health threats in the context of real-time challenges and changing dynamics, like rising temperatures, extended rainy seasons or drought – particularly in the ‘last mile.’ This will require us to reimagine and invest in a new research agenda driven by scientists on the frontlines of this climate-vector-borne disease nexus aimed at protecting those most vulnerable to its impact. Stronger action on the ground We need a committed, global push for research that not only tracks disease trends but actively explores robust intervention strategies that consider the full spectrum of climate impacts. This includes a holistic approach to hazard assessment, driven by research that examines the links between hazards, vulnerability and exposure so we can more accurately project the potential effects of climate change on malaria and NTDs. The climate crisis will only continue to put strain and pressure on already fragile health systems, diverting precious resources from other budget lines, including malaria and NTDs. With more evidence, we can break this cycle and protect the resources needed for disease response. Last week, the World Health Assembly adopted the WHO’s 14th Global Programme of Work, which prioritises the climate-health nexus. Member states also adopted the strongest resolution yet on climate change and health. Now we need to see even stronger action on the ground. Let’s marshal our collective resources and ingenuity to ensure that our responses are as adaptable as the diseases we’re striving to overcome. The time to act is now. This new WHO paper is not just a summary of data; it’s a call to action. It’s a directive for all of us involved in the fight against malaria and NTDs to look beyond our current horizons and plan for a future where climate change reshapes the landscape of global health. For the sake of the millions at risk, we must heed this call and act swiftly and decisively. It’s no small challenge, but one that we can overcome together. Dr Ibrahima Socé Fall is the Director of WHO’s Global NTD Programme. Dr Michael Adelkunle Charles is CEO of the RBM Partnership to End Malaria. Image Credits: Yoshi Shimizu, Billy Miaron/ WHO. WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
One Health is a ‘One World’ Agenda, Even as Negotiators Wrangle Over Inclusion in WHO Pandemic Accord 06/06/2024 Elaine Ruth Fletcher ‘There is no one way to implement One Health solutions:’ Eric Comte, at podium with panelists describing country experiences: (left to right) Benjamin Roche, Chloe Astbury, Arlette Dinde and moderator, Nina Jamal. Is One Health really an agenda of only the Global North? Panelists at an event last week, hosted by the Geneva Graduate Institute’s Global Health Center, think otherwise. They talked about how developing countries are putting One Health principles into practice to head off future disease outbreaks. One Health is critical to future prevention of outbreaks and pandemics, and wider application of One Health principles should be a common agenda of both the global North and South – even if negotiators continue to wrangle over its inclusion in the still-unfinished World Health Organization (WHO) pandemic agreement. Those were key messages emerging from a dialogue co-sponsored by the Global Health Center (GHC) together with the Geneva Health Forum on the sidelines of last week’s World Health Assembly. At WHA, negotiators received a new mandate from member states to continue talks to conclude a pandemic accord by the 2025 WHA at the latest. The talks are set to resume in July. The Geneva Health Forum, convened by the University of Geneva and partners on the first three days of the 2024 World Health Assembly, brings together key global health scientists and policymakers with medical practitioners and other field actors. During the last frenzied weeks of negotiations just before WHA, the inclusion of references to One Health principles in Article 5 of the draft text spurred opposition from some low- and middle income countries (LMICs) as well as some civil society organizations. In late May, 68 CSOs called on negotiators to ‘Reject One Health Instrument’ in the pandemic agreement. They argued that One Health provisions intended to boost pathogen surveillance and pandemic prevention could also enable developed countries to erect new trade barriers and data demands on developing countries, and impose more costly pandemic preventive measures which poorer countries could not afford to implement. Over 120 experts and civil society proponents shot back with an open letter of their own. They asserted that better recognition of One Health principles and practices is critical to prevent more deadly spillover of zoonotic diseases into human populations, which could cause the next pandemic, as well as more locally disease outbreaks that typically kill people in LMICs first of all. Many One Health projects already taking place in Africa, South-East Asia Nina Jamal, Four Paws International. “Is One Health really a global North agenda?” asked moderator Nina Jamal, International Head of Pandemics and Campaign Strategies at Four Paws International, which also co-sponsored the event. The soft-spoken Jamal, a Lebanese-Austrian with a wealth of experience straddling such ‘North’ and ‘South’ polarities, has become one of the leading advocates One Health in the pandemic agreement, patiently sitting through countless late-night sessions, and speaking one-on-one with delegates about their views and concerns over more than two years of negotiations. “The perception is that One Health involves a set of obligations imposed by high income countries on low-income ones. But is all the knowledge and expertise on One Health in the global North?” asked Jamal. At the GHC event, researchers working in countries as diverse as the Cote d’Ivoire, Guinea, Mexico, China and the Democratic Republic of Congo, described how they they are putting One Health principles into practice to promote better animal surveillance, reduced deforestation, and improved practices around wildlife management in food markets and trade – and document related health benefits. Most recent outbreaks linked to lack of ‘One Health’ measures Live chickens await slaughter at a traditional market in Lanzhou, China. Along with mammals, live poultry also harbor pathogens that can infect humans, in instances such as the H5N1 outbreak of avian influenza of the late 1990s. Most recent outbreaks of disease that have hit developing countries harder than developed ones are somehow related to an overall dearth of One Health measures that needs to be addressed, the experts asserted. Examples range from Ebola, Lassa fever and mpox in Africa, to SARS and Nipa virus in Asia, and expanding circles of dengue virus, Chagas disease, in Latin America. Countries in the global North are not immune either. That was evident in the 2009 H1N1 [swine flu] pandemic, that first appeared in Mexico and the United States, and ultimately infected up to 80 million people. More recently the US has seen a surge in H5N1 cases among dairy herds, as well as infections in some farm workers; in the case of the latter, poor sanitation around milking machines has been named as a key transmission factor. Milking a cow in Texas. Avian influenza is spreading among US cattle, most likely during milking. In fact, some 75% of recent disease outbreaks and epidemics can largely be traced to zoonotic spillovers to human populations – related to deforestation, poor regulation of domestic animal production, as well as poorly regulated wildlife markets and consumption, Jamal points out citing a widely held view amongst public health experts. Aims and practices of One Health Training farmers in judicious use of antibiotics, vaccines and surveillance of animals for unusual disease outbreaks are all important One Health practices. The overarching aim of One Health, according to WHO, is to “balance and optimize the health of people, animals and the environment… It involves veterinary, public health and environmental sectors.” One Health approaches most commonly involve practical efforts to improve: Animal and ecosystem surveillance for pathogens of risk to humans and not only for species protection; Community water, waste and sewage management to improve human hygiene and prevent the breeding of vector-borne diseases, from dengue to zika and malaria. Sustainable milk and meat production, including sanitation and management of waste. Poor waste management in concentrated pig farming was, for instance, named as one possible source for the 2009 eruption H1N1 (Swine flu). Animal use of antibiotics and other antimicrobial agents whose efficacy has been eroded by rampant veterinary overuse, leading to growing threats to human health from antimicrobial resistance (AMR). Forests: preventing rampant deforestation that drives rodents, insects and other wild animals and their pathogens into human communities – driving spread of dengue, Chagas, and more recently nipa virus; Deforestation fragments wild animal habitats, increasing pathogen contact and risks to humans. Wild animal breeding, trade, and consumption. The spread of the first SARS virus from bats to palm civets and then to humans via wild animal markets is well documented. A number of prominent scientists attribute the emergence of SARS-CoV2 to similar pathways – although others disagree. In Africa, the hunting and consumption of bushmeat (from reptiles to mammals) has been linked to the emergence of major diseases such as HIV and Ebola, as well as mpox – although bushmeat is also valued as an important protein source. Health and wildlife surveillance disconnect Arlette Dinde, Côte d’Ivoire researcher (second from right) describes the continuing health-wildlife research disconnect. Despite much debate in WHO pandemic talks about improving disease surveillance to identify emerging pathogen risks earlier – the very first link in the surveillance chain remains broken, noted Arlette Dinde a research associate at the Swiss Centre for Scientific Research in Côte d’Ivoire. Dinde recently led a 10-year, multi-country review of research of studies on wildlife in Côte d’Ivoire covering 2012-2022, including both the period of the West African Ebola epidemic (2014-2016) as well as COVID-19. The study identified a trend towards more wildlife research over that decade – but still little attention to the public health threats. “Research is still much more focused on biodiversity and conservation, and much less about the health and food security aspects,” Dinde said, noting that zoonoses and public health risks were mentioned in only about 22% of the research on wildlife and biodiversity identified. Conversely, “only about 5% of [public-health focused] research addressed aspects of wildlife disease surveillance,” she said. Not surprisingly then, government wildlife or farm sector planning doesn’t typically include the health sector, she found. She lamented the “lack of collaboration between the different sectors in the government, when we could have a great opportunity to push the wildlife sector into the public health system, and have a national One Health plan, around which we could coordinate.” A dangerous pathogen found in Mexico could ‘be in Geneva’ next Roche: a wild animal pathogen in Asia or Latin America can quickly be transported to Europe. PREZODE, an international One Health network is working with governments in 25 countries around the world, including projects to curb dangerous deforestation patterns, which drive more wild animals, rodents and insects into villages, towns and cities every year. Efforts include a pilot effort in Thailand for “reforestation by communities that can actually try to reduce diseases, and especially rodent borne diseases, which is generally a group of diseases that don’t receive enough attention,” said Benjamin Roche, co-founder of the international NGO. Similarly the group is trying to develop a “win-win strategy” in Mexico’s Yucatan province, a sensitive tropical area that is also one of the most deforested in the world, to improve biodiversity protection in ways that also reduce human exposure to zoonotic diseases. “I’s not just about biodiversity protection,” Roche underlined. “It’s also about education in some very remote rural communities, working closely with local NGOs in order to try to fit together real integrative prevention strategies in place.” It’s also about global health security, he underlined, in light of the speed at which emerging pathogens and outbreaks can travel: ”The Yucatan Penninsula is connected with Mexico by 10 flights a day, and Mexico City is 25 million people. So you can imagine that when you have a pathogen jumping from Yucatan to Mexico City – it is almost already in Geneva.” Changing norms around wildlife markets Most early, confirmed cases of SARS CoV2 were traced back to Wuhan’s Wholesale Seafood Market – although a definite animal ‘vector’ has never been established. Nowhere was that principle demonstrated better than in China during the SARS-CoV 2 pandemic and the rapid international transmission of COVID-19. Since that time, China has cracked down on wildlife markets, which were often patronized by more affluent groups which considered wild animal meat as a kind of “prestige” cuisine, noted Chloe Clifford Astbury, a researcher at the York University School of Public Health. China has also rolled back its former support for the commercial breeding of certain wildlife species, which may have played a role as intermediary hosts of SARS-CoV2, transmitting the virus to humans, particularly in the early days of the outbreak in Wuhan. “But wildlife is still used and traded for other uses, just not necessarily for consumption,” she added. In comparison, in central African countries like the DRC, wildlife, or bushmeat consumption is more widely a practice of lower income and rural communities “who depend on it as a source of protein, or as a source of income, for example, selling in the markets.” While there are laws on the books preventing hunting of certain species, on-the-ground convictions are relatively rare. Community involvement is key Community inclusion in One Health activities is critical. But Dinde, like Roche, stressed the importance of community involvement in development of government regulations – if One Health-related measures are to succeed. For instance, she said that she doesn’t support blanket bans on bushmeat consumption – noting that such decrees are widely ignored. And many African communities still rely on bushmeat as a “vital source of protein, she said. Following Côte d’Ivoire’s banning of bushmeat consumption during the 2014-16 West African Ebola epidemic, she led a paper evaluating its impacts, which found: “While fish and edible mushrooms seem to have filled related protein deficits in the households assessed… constraints in availability and utilization of these alternative sources build an inconsistent basis to fulfill the nutritional needs [of rural populations]. Such bans, therefore, needed to be accompanied by a stronger development of fish farming and livestock production to improve access to vital protein sources and insure that nutrition is not undermined. At the same time, communities need to be more sensitized to the risks that some bushmeat poses and how to minimize those – for instance by avoiding consumption of animals found dead in a forest – which may have perished due to disease. “Most of the time, communities will eat those animals [found dead in the forest] now,” she says, noting that there is little awareness of the risks involved. One Health: why should we tackle it in the pandemic agreement? Linking animal and human health surveillance is critical to pandemic prevention. Paradoxically, a clause regarding the “involvement of communities” in One Health remains a key disputed clause in the pandemic text, noted Jamal. And despite animal-borne diseases pose the leading pandemic risks of the future, some member states continue to argue that One Health doesn’t belong in the pandemic treaty at all, she added. “They ask ‘why should we tackle this in the Pandemic Instrument,” she said. “They say, why not just give pieces of One Health to WHO, to the WOAH [World Organization for Animal Health] to UNEP, to FAO, and , etc.. and on the national level, just leave them in their boxes?” One Health in draft Pandemic Agreement: Yellow text signals ‘convergence, but not agreement’. No agreement on community involvement. Historically, activities at country level, and globally, have “been quite siloed,” Astbury notes. “Both at the national and global level, there’s so much to be gained from intersectoral collaboration and so much loss when there’s really siloed ways of working,” she said. “Take surveillance, for example, there’s so much potential additional knowledge so much sharing is good practice that you can get through an integrated surveillance system – compared to a siloed one. “I know a lot of countries are struggling with implementing something like that. Historically, things have been quite siloed, and they are now trying to bring them together. “So coming together and thinking about trade offs and co-benefits is really important. And to do that, you can’t work in that kind of a siloed way.” Adds Roche: “An outbreak somewhere, even quite remote, can be a pandemic very quickly. So the vertical approach is not working any more. “Look at COVID-19, which was just a couple of cases in December, and it was a worldwide pandemic just four months later. It’s just an illustration of how quick and viral these things can be. It’s not like 20 years ago, we have a lot of small threats emerging all of the time. It means we have to change our approach.” Concluded Eric Comte, director of the Global Health Forum, which co-sponsored the event: “One Health is a bridge, a bridge between different scientific disciplines and a bridge between science and policy. There is no one single One Health solution, but stage by stage we can make progress.” Image Credits: Arend Kuester/Flickr, Flickr/M M, Josh Kelahan, PREZODE, PREZODE , PREZODE , WHA . Assistive Technology Report Brings More Transparency to Market 06/06/2024 Zuzanna Stawiska For many, access to assistive technology can enable independent everyday life. Only one in five of the people in need of hearing aids and prostheses worldwide can access them, according to a new report by ATscale, a global partnership for assistive technologies and the Clinton Health Access Initiative (CHAI). Assistive technology (AT) is any device and related systems that can help with everyday activities, improving or restoring the capabilities of a person’s body, ranging from eyeglasses, access ramps, prostheses or smartphones for functionalities such as the text-to-speech option. The report, issued on the first-ever Day for Assistive Technology, aims to make assistive technology markets more transparent and easier to navigate for the public sector and producers. The hope is that comprehensive information will facilitate the choice of quality products, especially for governments in low- and middle-income countries, and encourage companies to expand their reach to new regions of operation, explained Pascal Bijleveld, CEO of ATscale in an interview for Health Policy Watch. “It’s really about addressing one of the bottlenecks to access, which is the lack of transparency in the markets about what products are available, what are the price ranges, what’s the quality, and so on and so forth,” Bijleveld said. Many governments lack the capacity to analyse and understand each of the markets and may make sub-optimal product choices. It is also essential to raise awareness about the benefits of assistive technology and to start public and private initiatives to ensure more people, especially in low-income countries, can attain the AT they need. Large gap in access Getting a AT of need is often the key to a more independent, full life for people with disabilities, unlocking a possibility to live independently, meet with family and friends, study, or work. Globally, 2.5 billion people need at least one assistive product with the number expected to reach 3.5 billion by 2050 as the world population ages, WHO’s and UNICEF’s report shows. Even though 90% of people in need of an AT in high-income countries can access it, the number drops drastically to only 10% in low- and middle-income countries. There is a nine-to-one return on investment from providing AT, thanks to unlocked educational outcomes, better paid employment and lower longer-term healthcare costs, an ATscale study from 2022 highlights. The report systematically analyses markets for several most popular technologies: wheelchairs, glasses, augmentative communication, screen readers, and smartphones. Hearing aids, glasses and other assistive technologies can be prohibitively expensive. Taken for granted in wealthy countries, these simple technologies are out of reach for millions globally. It lists the product types available, describes market specifics and enumerates some of the most important features. For hearing aids, for example, approximately 20 million units are sold annually, with the main market drivers being the ageing population. When picking the right device, it’s important to consider its ability to manage background noise and acoustic loops, its resilience against mild shocks, dust or rain, volume control and overall design. Those and other features are tested by several control agencies; to help navigate the market, the report provides a comprehensive list of producers and certificates held by their devices. The report is only the first step, Bijleveld said and will be changed over the next couple of months into “a web-based platform that will be continuously updated”. Producers themselves will want to keep this interactive source of information up to date as a potential advertisement for their products and a guide to the overall market situation. Raising awareness about the benefits of ATs is on the top of ATscale’s agenda. ”People need to get the word out there,” Bijleveld stressed. Image Credits: CC. Global Leaders Appeal for More Resources Ahead of UN meeting on Antimicrobial Resistance 06/06/2024 Kerry Cullinan Drug-resistant bacteria have developed from years of over-prescription of antibiotics. With less than four months to the United Nations High-Level Meeting (HLM) on Antimicrobial Resistance (AMR), global leaders have proposed a variety of measures to address the growing threat of pathogens that are resistant to antibiotics. The recently published zero draft of the political declaration for the meeting aims to reduce global deaths caused by bacterial AMR by 10% by 2030 (using 2019 as the baseline). Mia Mottley, Prime Minister of Barbados and chairperson of the Global Leaders Group on AMR, called for “adequate, predictable and sustainable financing” to address the problem, including financing for research and development for new antibiotics and the implementation of national action plans on AMR, especially in low- and middle-income countries. “Fundamentally, we must focus on prevention across all sectors – clean water, safe and effective sanitation, food security, infection prevention and control in all settings,” Mottley told a lunchtime roundtable during last week’s World Health Assembly. Prime Minister of Barbados Mia Mottley, who chairs the Global Leaders Group on AMR “I believe that we should establish an independent panel to monitor and report on the science and the evidence to facilitate collaborative and coordinated action against AMR,” She also called for the quadripartite joint secretariat on AMR to be formalised and adequately resourced. This is made up of the World Health Organization (WHO), the UN Food and Agriculture Organisation (FAO), UN Environment Programme (UNEP), and the World Organisation for Animal Health (WOAH). The agricultural sector is responsible for the vast majority of antibiotic overuse, leading to drug resistance. Threatens to ‘unwind century of medical progress’ “In 2019, 1.3 million deaths resulted directly from bacterial AMR, more than two every minute,” WHO Director-General Dr Tedros Adhanom Ghebreyesus told the meeting. “AMR threatens to unwind the century of medical progress and also threatens animal health, global food production, food security, and the environment.” Dr Jean Kaseya, Director-General of Africa CDC, noted over one million deaths in Africa were associated with AMR and 250,000 caused by ARM. “Only 1.3% of our labs in Africa are able to perform bacterial resistance testing. It means this data that I’m sharing with you is an underrepresentation of the reality in Africa,” said Kaseya. Four years ago, the African Union Assembly established a task force to control AMR and recommended that all member states implement national action plans. “But less than 10% of a member states have national action plans that are fully funded and implemented,” he added. Kaseya appealed to The Global Fund to expand its mandate from HIV, TB, and malaria to include AMR. Professor Sally Davies, UK Special Envoy on AMR Professor Sally Davies, the UK Special Envoy on AMR and a member of the Global Leaders Group, called for the high-level meeting to “truly address the needs of the most vulnerable communities, offering clear support to low and middle-income countries” that carry the greatest burden of this antibiotic emergency and need fair and equitable access to antibiotics and diagnostics. Surviving AMR Vanessa Carter developed a drug-resistant infection after a car crash cost her an eye. South African Vanessa Carter, chair of WHO Taskforce of AMR Survivors, shared her nightmare of being unable to shake an infection after being seriously injured in a car crash in Johannesburg and losing her right eye. The infection turned out to be the drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA). Hospital patients, people with wounds, and those who have surgery and medical devices implanted in their bodies are particularly at risk of MRSA. Today, I was privileged to share my lived experience of #AMR at the #WHA77 & talk about the work we have already achieved with the @WHO Task Force of AMR Survivors since its inaugural meeting in October 2023 Patients, carers & survivors help to demonstrate the real-world impact… pic.twitter.com/k9onObOpm5 — Vanessa Carter 🇬🇧🇿🇦 (@_FaceSA) May 31, 2024 Carter, who spent a month in hospital, had a prosthetic eye inserted and a number of surgeries. “In my sixth year of surgeries, and my fourth prosthetic [eye], I went out shopping one day, I came back to the car and I felt moisture on my face. When I pulled down the rearview mirror, I saw this pus seeping out of the cheek of the prosthetic,” Carter told the roundtable meeting. Her doctor told her she needed emergency surgery, but two weeks’ later the infection came back again. “I was under the care of different types of specialists, an ENT surgeon, ophthalmologist, plastic surgeon, maxillofacial surgeon, each of them prescribing antibiotics during surgeries,” she added. After almost a year of continued infections, doctors removed the prosthetic eye and sent it for testing and it was found to be contaminated with MRSA. What followed was a long and harrowing process during which the infection got into Carter’s bones before she was finally cured. “I’ve been an advocate for the last 11 years and, most recently, we’ve established the WHO Task Force of AMR Survivors,” said Carter. “Our biggest objective is to bring the human impact. When policy makers and members of the public understand exactly what it is, we can we can empower them. One of the documents we have worked on is a strategic technical guidance document for meaningful patient involvement. I would encourage you to go take a look at it.” World Will Permanently Exceed 1.5°C Tipping Point Before 2030 – At Current Carbon Emissions Rate 05/06/2024 Elaine Ruth Fletcher World reaches record high for annual temperatures over past 12 months – as 1.5°C tipping point approaches. ‘Extortion level’ capital costs put renewables out of reach in most developing economies; fossil fuel companies rake in record profits; and world reels from record heat, freak floods and drought, says UN Secretary General. New climate data released Wednesday shows virtually all key global warming parameters, including land and sea temperatures at all time record high levels for May, as well as for the past year. There’s an 80% likelihood that in at least one of the next five years, the world will temporarily exceed the 1.5°C limit set by the 2015 Paris agreement, said the World Metereological Organization. And at current emissions rates, the world will permanently breach the 1.5° C limit before 2030, warned UN Secretary General Antonio Guterres in a stark message on climate change, coinciding with World Environment Day. “New data from leading climate scientists released today shows the remaining carbon budget to limit long term warning to 1.5 C is now around 200 billion tons – that is the maximum amount of carbon dioxide that the Earth’s atmosphere can take – if we are to have a fighting chance of staying within the limits,” Guterres said. His comments were based on projections released today by WMO and the European Union’s Copernicus climate observatory. “And the truth is, we are burning through the budget at reckless speed, spewing out around 40 billion tons of carbon dioxide a year,” he said urging people “to do the math.” “At this rate, the entire carbon budget will be passed before 2030,” he said in an address was delivered from New York City’s Museum of Natural History – to underline the point that the human species, like dinosaurs, faces a real extinction threat. World’s carbon ‘budget’ surpassed before 2030 UN Secretary General delivers a major address on climate Wednesday 5 June. To avoid permanently breaching the 1.5°C tipping point, global emissions need to fall by 9% every year until 2030, he said. “But they are heading in the wrong direction. Last year, they rose by 1%. “Almost 10 years since the Paris Agreement was adopted, the target of limiting long term global warming to 1.5 degrees Celsius is hanging by a thread. Meanwhile, the godfathers of climate chaos, the fossil fuel industry, rake in record profits supported by a system of trillions [of dollars] in taxpayer funded subsidies.” ‘Extortion-level’ capital costs put green energy out of reach in developing countries Hospital in Johannesburg, South Africa with solar panels: Investments in African renewables was a woeful 1% even as costs globally tumble. It is money that is driving the world to “climate hell”, the UN Secretary General said, calling for a broad overhaul of finance priorities amongst G20 and G7 countries, as well as in private banks and multilaterals. Investments in African renewables represent just 1% of the world’s installed PV solar capacity – while oil and gas profiteers rake the continent for fossil fuels, he noted, citing recent data from the International Energy Agency. “Extortion level capital costs are putting renewables virtually out of reach for most developing and emerging economies – astoundingly and despite the renewables boom of recent years,” Guterres declared. “Clean energy investments in developed developing and emerging economies outside of China have been stuck at the same levels since 2015. Last year, just 15% of new clean energy investment went to emerging markets and developing economies outside China, countries representing nearly two thirds of the world’s population. “And Africa was less than 1% of [PV solar] installations – despite its wealth of natural resources, and vast renewables potential.” All that is coming at a time when globally, clean energy investments reached a record high last year, with wind and solar power growing faster than any other electricity source in developed economies, he noted. Hottest month and year on record Record high sea temperatures are changing ocean and air currents, bleaching corals, threatening ice caps – all accelerating the approach of climate tipping points. May 2024 also was the hottest day in recorded history – marking 12 consecutive months of the hottest weather for the planet ever on record, Guterres noted, citing the fallout that is also being felt from Delhi to the Americas – in terms of record temperatures on the Indian subcontinent, and fierce, unpredictable storms and flooding in southern Brazil. The new WMO report, also released Wednesday, backs that up with detailed data on the unprecedented levels of temperature rise on land as well as on the seas. The WMO report was led by the UK Met Service. Further data on global warming trends was released by the European Union’s Copernicus Climate Service. Based on that data, the global average temperature for the last 12 months (June 2023 – May 2024) is the highest ever on record, at 1.63°C above the 1850–1900 pre-industrial average. And crossing 1.5°C is not merely a matter of crossing a political target, Guterres stressed. “Scientists have alerted us that temperatures rising higher would likely mean the collapse of the Greenland Ice Sheet and the West Antarctic Ice Sheet with catastrophic sea level rise,” he said, And not only that, but also the “destruction of tropical coral reef systems and livelihoods of 300 million people; the collapse of the Labrador Sea currents that would further disrupt weather patterns in Europe; and widespread permafrost melt that will release devastating levels of methane – one of the most potent heat trapping gasses.” Health effects increasingly evident – impacting the poorest and vulnerable Water shortage in Ethiopia. Droughts, flooding and heat waves all create acute health impacts, as well as exacerbating chronic diseases, like cardiovascular disease. Even today, as humankind pushes planetary boundaries to the brink- shattering global temperature records are being recorded around the world, he pointed out. “Already the brutal heatwave has baked Asia with record temperatures, shriveling crops, closing schools and killing people. Cities from New Delhi to Bamako to Mexico City are scorching. Here in the West severe storms have destroyed communities and lives. “We have seen drought and disaster declared across southern Africa and extreme rains flood the Arabian Peninsula, East Africa and Brazil. “And the mass global coral bleaching caused by unprecedented ocean temperatures – soaring past the worst predictions of scientists,” he said, noting that the cost of climate “chaos” could rise to at least $30 trillion by 2050.” And while the rich can huddle inside air conditioned bubbles, at least much of the time, those least responsible for the crisis bear its brunt, he noted. “Extreme events turbocharged by climate change are piling up – destroying lives, families’ economies and hammering health, wracking sustainable development, forcing people from their homes and rocking the foundations of peace and security as people are displaced and vital resources are depleted.” Appeal to G7 and G20 to fix broken financial system ‘Better, bigger and bolder’ commitments to green energy needed from multilateral development banks. To reverse current trends, Guterres called on world leaders, and particularly G7 leaders meeting nexxt week in Italy, as well as the G20, in Rio in November, to commit to ending coal production by 2030 and reduce oil and gas production by 60% – as compared to trillions in fossil fuel subsidies. The world’s leading economies also should: Set up a “high integrity” system for carbon taxes and markets; Relieve the debt burden in developing economies so that investment can flow into green forms of energy; Commit to finally filling the coffers of the Green Energy Fund, with the $100 billion in funds agreed to in previous Climate Conferences, for developing countries. He appealed to private financial institutions to stop funding coal, oil and gas projects – while the G7 and G20 countries should use their influence with multilateral development banks to make “better, bigger and bolder” commitments to green energy infrastructure. “The International Energy Agency reports that clean energy investments in developing and emerging economies beyond China need to reach up to $1.7 trillion a year by the early 2030s. “In short, we need a massive expansion of affordable problem to public and private finance to fuel ambitious new climate plans and deliver clean, affordable energy for all,” he said, pointing to the UN Summit of the Future planned for September “to push reform of the international financial architecture.” Meanwhile, private financial institutions should stop “”bankrolling fossil fuel destruction and start investing in a global renewable revolution,” while shareholders press for disclosure of engagements on fossil fuel multinationals – which have pressed on the gas, rather than releasing the pedal, investing a mere 2.5% in renewable projects, on average last year. Ban advertising of ‘unhealthy’ fossil fuels, as with tobacco Fossil fuels kill, like tobacco. Business and government leaders, moveover, need to confront disinformation and “greenwashing” by the fossil fuel industry, more aggressively. “Many governments restrict or prohibit advertising for products that are dangerous to human health like tobacco,” he pointed out. Some are now doing the same for fossil fuels. “I urge every country to ban advertising from fossil fuel companies. And I urge news media and tech companies to stop taking fossil fuel advertising. Embrace clean technologies Cycling in Fortaleza, Brazil – the city strengthened its active transport system, which reduces carbon emissions from motor vehicles. Meanwhile, he said, the general public can press on demand-side levers. “All of us can make a difference by embracing clean technology, phasing down fossil fuels in our own lives, and using our power as citizens to push for systemic change in the fight for a Livable Future. “People everywhere are far ahead of politicians. Make your voices and your choices count your friends. We do have a choice, creating tipping points for climate progress or gaining tipping points for climate disaster.” Image Credits: World Metereological Organization, Health Care Without Harm , WMO , Oxfam East Africa, WHO FCTC, City of Fortaleza. Strengthening Our Response to Malaria and Neglected Tropical Diseases in a Warming World 05/06/2024 Ibrahima Socé Fall & Michael Adelkunle Charles These children from Savai’i Island, Samoa, are protected by a mosquito net while they sleep. Climate change is perhaps the greatest threat to human health. In a warming world, with changing and unpredictable weather patterns, its effects are all around us. In 2022, Pakistan experienced the worst floods in the country’s history, placing much of the country under water and giving way to a fivefold increase in the country’s rate of malaria transmission. Earlier this year, Brazil declared a state of emergency as its national healthcare system buckled under the pressures of an outbreak of dengue, a neglected tropical disease (NTD) carried by mosquitoes. Cases continue to rise and the outbreak shows no sign of stopping. But Brazil is not alone. Over the past two decades, dengue cases have increased eightfold, with the mosquitoes that carry it thriving in areas where climate change has made temperatures higher and precipitation more abundant. Despite these daily reminders, there is much we do not understand about the impact climate change is exacting on malaria and NTDs, both of which disproportionately impact low-income countries (LICs). An ongoing effort to rid the world of these debilitating diseases by understanding the impacts of climate change isn’t just important – it’s imperative. Evidence gaps An unprecedented scoping review highlights significant gaps in evidence. It was conducted by the World Health Organization (WHO) Task Team on Climate Change, NTDs and Malaria, in partnership with Reaching the Last Mile, a portfolio of global health initiatives driven by the philanthropy of United Arab Emirates President Sheikh Mohamed bin Zayed Al Nahyan. Spanning 42,693 articles from the past decade, the review correlates climate fluctuations with changing disease patterns, confirming that changing temperature and rainfall patterns will shift the transmission windows and geographies of malaria, dengue and chikungunya. The research also reveals that, as our planet warms, the poorest and most vulnerable communities are poised to suffer even more. It also highlights that our research agenda is imbalanced, with studies historically focused on where disease burden is low and access to quality healthcare is high. This is not merely a health issue but a profound injustice that compounds vulnerabilities among those least equipped to bear them. Given the complex and nonlinear ways these diseases interact with changing climates, the importance of closing our gap in understanding is clear. As we already see with dengue in Brazil – and will continue to see in other areas for years to come – diseases are being transmitted faster and farther than before as vectors like mosquitoes expand to regions previously unexposed to these diseases. This could lead to new outbreaks in populations without any natural resistance or existing health infrastructure to manage such diseases. It’s only further complicated by increased displacement and migration as a result of a changing climate. Adaptation and mitigation Health officials speak to community members in Tana River County, Kenya, about the ongoing oral cholera vaccination campaign. Despite the clear risk, our understanding of how to mitigate or adapt to the impact of climate change on malaria and NTDs is limited. Adaptation and mitigation strategies were discussed in only a fraction of the scientific literature reviewed by the WHO Task Team. This needs to change. A new research agenda is crucial to inform evidence-based adaptation and mitigation strategies. In a world acutely aware of the effects of climate change, this all matters immensely if we are to preserve our gains and investments. As global citizens and stakeholders in global health – whether policymakers or researchers, NGOs, funders, or community leaders— we must adapt our strategies and responses not just to the diseases as we’ve known them, but to how they will evolve in a changing climate. This will require innovative approaches to our public health interventions as dynamic as the challenges they aim to counter. We must build resilient, climate-responsive health systems, surveillance programs and intervention strategies to mitigate against or adapt to the immediate-short-term and long-term effects of climate change on malaria and NTDs. We must ensure communities have the resources to respond to health threats in the context of real-time challenges and changing dynamics, like rising temperatures, extended rainy seasons or drought – particularly in the ‘last mile.’ This will require us to reimagine and invest in a new research agenda driven by scientists on the frontlines of this climate-vector-borne disease nexus aimed at protecting those most vulnerable to its impact. Stronger action on the ground We need a committed, global push for research that not only tracks disease trends but actively explores robust intervention strategies that consider the full spectrum of climate impacts. This includes a holistic approach to hazard assessment, driven by research that examines the links between hazards, vulnerability and exposure so we can more accurately project the potential effects of climate change on malaria and NTDs. The climate crisis will only continue to put strain and pressure on already fragile health systems, diverting precious resources from other budget lines, including malaria and NTDs. With more evidence, we can break this cycle and protect the resources needed for disease response. Last week, the World Health Assembly adopted the WHO’s 14th Global Programme of Work, which prioritises the climate-health nexus. Member states also adopted the strongest resolution yet on climate change and health. Now we need to see even stronger action on the ground. Let’s marshal our collective resources and ingenuity to ensure that our responses are as adaptable as the diseases we’re striving to overcome. The time to act is now. This new WHO paper is not just a summary of data; it’s a call to action. It’s a directive for all of us involved in the fight against malaria and NTDs to look beyond our current horizons and plan for a future where climate change reshapes the landscape of global health. For the sake of the millions at risk, we must heed this call and act swiftly and decisively. It’s no small challenge, but one that we can overcome together. Dr Ibrahima Socé Fall is the Director of WHO’s Global NTD Programme. Dr Michael Adelkunle Charles is CEO of the RBM Partnership to End Malaria. Image Credits: Yoshi Shimizu, Billy Miaron/ WHO. WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Assistive Technology Report Brings More Transparency to Market 06/06/2024 Zuzanna Stawiska For many, access to assistive technology can enable independent everyday life. Only one in five of the people in need of hearing aids and prostheses worldwide can access them, according to a new report by ATscale, a global partnership for assistive technologies and the Clinton Health Access Initiative (CHAI). Assistive technology (AT) is any device and related systems that can help with everyday activities, improving or restoring the capabilities of a person’s body, ranging from eyeglasses, access ramps, prostheses or smartphones for functionalities such as the text-to-speech option. The report, issued on the first-ever Day for Assistive Technology, aims to make assistive technology markets more transparent and easier to navigate for the public sector and producers. The hope is that comprehensive information will facilitate the choice of quality products, especially for governments in low- and middle-income countries, and encourage companies to expand their reach to new regions of operation, explained Pascal Bijleveld, CEO of ATscale in an interview for Health Policy Watch. “It’s really about addressing one of the bottlenecks to access, which is the lack of transparency in the markets about what products are available, what are the price ranges, what’s the quality, and so on and so forth,” Bijleveld said. Many governments lack the capacity to analyse and understand each of the markets and may make sub-optimal product choices. It is also essential to raise awareness about the benefits of assistive technology and to start public and private initiatives to ensure more people, especially in low-income countries, can attain the AT they need. Large gap in access Getting a AT of need is often the key to a more independent, full life for people with disabilities, unlocking a possibility to live independently, meet with family and friends, study, or work. Globally, 2.5 billion people need at least one assistive product with the number expected to reach 3.5 billion by 2050 as the world population ages, WHO’s and UNICEF’s report shows. Even though 90% of people in need of an AT in high-income countries can access it, the number drops drastically to only 10% in low- and middle-income countries. There is a nine-to-one return on investment from providing AT, thanks to unlocked educational outcomes, better paid employment and lower longer-term healthcare costs, an ATscale study from 2022 highlights. The report systematically analyses markets for several most popular technologies: wheelchairs, glasses, augmentative communication, screen readers, and smartphones. Hearing aids, glasses and other assistive technologies can be prohibitively expensive. Taken for granted in wealthy countries, these simple technologies are out of reach for millions globally. It lists the product types available, describes market specifics and enumerates some of the most important features. For hearing aids, for example, approximately 20 million units are sold annually, with the main market drivers being the ageing population. When picking the right device, it’s important to consider its ability to manage background noise and acoustic loops, its resilience against mild shocks, dust or rain, volume control and overall design. Those and other features are tested by several control agencies; to help navigate the market, the report provides a comprehensive list of producers and certificates held by their devices. The report is only the first step, Bijleveld said and will be changed over the next couple of months into “a web-based platform that will be continuously updated”. Producers themselves will want to keep this interactive source of information up to date as a potential advertisement for their products and a guide to the overall market situation. Raising awareness about the benefits of ATs is on the top of ATscale’s agenda. ”People need to get the word out there,” Bijleveld stressed. Image Credits: CC. Global Leaders Appeal for More Resources Ahead of UN meeting on Antimicrobial Resistance 06/06/2024 Kerry Cullinan Drug-resistant bacteria have developed from years of over-prescription of antibiotics. With less than four months to the United Nations High-Level Meeting (HLM) on Antimicrobial Resistance (AMR), global leaders have proposed a variety of measures to address the growing threat of pathogens that are resistant to antibiotics. The recently published zero draft of the political declaration for the meeting aims to reduce global deaths caused by bacterial AMR by 10% by 2030 (using 2019 as the baseline). Mia Mottley, Prime Minister of Barbados and chairperson of the Global Leaders Group on AMR, called for “adequate, predictable and sustainable financing” to address the problem, including financing for research and development for new antibiotics and the implementation of national action plans on AMR, especially in low- and middle-income countries. “Fundamentally, we must focus on prevention across all sectors – clean water, safe and effective sanitation, food security, infection prevention and control in all settings,” Mottley told a lunchtime roundtable during last week’s World Health Assembly. Prime Minister of Barbados Mia Mottley, who chairs the Global Leaders Group on AMR “I believe that we should establish an independent panel to monitor and report on the science and the evidence to facilitate collaborative and coordinated action against AMR,” She also called for the quadripartite joint secretariat on AMR to be formalised and adequately resourced. This is made up of the World Health Organization (WHO), the UN Food and Agriculture Organisation (FAO), UN Environment Programme (UNEP), and the World Organisation for Animal Health (WOAH). The agricultural sector is responsible for the vast majority of antibiotic overuse, leading to drug resistance. Threatens to ‘unwind century of medical progress’ “In 2019, 1.3 million deaths resulted directly from bacterial AMR, more than two every minute,” WHO Director-General Dr Tedros Adhanom Ghebreyesus told the meeting. “AMR threatens to unwind the century of medical progress and also threatens animal health, global food production, food security, and the environment.” Dr Jean Kaseya, Director-General of Africa CDC, noted over one million deaths in Africa were associated with AMR and 250,000 caused by ARM. “Only 1.3% of our labs in Africa are able to perform bacterial resistance testing. It means this data that I’m sharing with you is an underrepresentation of the reality in Africa,” said Kaseya. Four years ago, the African Union Assembly established a task force to control AMR and recommended that all member states implement national action plans. “But less than 10% of a member states have national action plans that are fully funded and implemented,” he added. Kaseya appealed to The Global Fund to expand its mandate from HIV, TB, and malaria to include AMR. Professor Sally Davies, UK Special Envoy on AMR Professor Sally Davies, the UK Special Envoy on AMR and a member of the Global Leaders Group, called for the high-level meeting to “truly address the needs of the most vulnerable communities, offering clear support to low and middle-income countries” that carry the greatest burden of this antibiotic emergency and need fair and equitable access to antibiotics and diagnostics. Surviving AMR Vanessa Carter developed a drug-resistant infection after a car crash cost her an eye. South African Vanessa Carter, chair of WHO Taskforce of AMR Survivors, shared her nightmare of being unable to shake an infection after being seriously injured in a car crash in Johannesburg and losing her right eye. The infection turned out to be the drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA). Hospital patients, people with wounds, and those who have surgery and medical devices implanted in their bodies are particularly at risk of MRSA. Today, I was privileged to share my lived experience of #AMR at the #WHA77 & talk about the work we have already achieved with the @WHO Task Force of AMR Survivors since its inaugural meeting in October 2023 Patients, carers & survivors help to demonstrate the real-world impact… pic.twitter.com/k9onObOpm5 — Vanessa Carter 🇬🇧🇿🇦 (@_FaceSA) May 31, 2024 Carter, who spent a month in hospital, had a prosthetic eye inserted and a number of surgeries. “In my sixth year of surgeries, and my fourth prosthetic [eye], I went out shopping one day, I came back to the car and I felt moisture on my face. When I pulled down the rearview mirror, I saw this pus seeping out of the cheek of the prosthetic,” Carter told the roundtable meeting. Her doctor told her she needed emergency surgery, but two weeks’ later the infection came back again. “I was under the care of different types of specialists, an ENT surgeon, ophthalmologist, plastic surgeon, maxillofacial surgeon, each of them prescribing antibiotics during surgeries,” she added. After almost a year of continued infections, doctors removed the prosthetic eye and sent it for testing and it was found to be contaminated with MRSA. What followed was a long and harrowing process during which the infection got into Carter’s bones before she was finally cured. “I’ve been an advocate for the last 11 years and, most recently, we’ve established the WHO Task Force of AMR Survivors,” said Carter. “Our biggest objective is to bring the human impact. When policy makers and members of the public understand exactly what it is, we can we can empower them. One of the documents we have worked on is a strategic technical guidance document for meaningful patient involvement. I would encourage you to go take a look at it.” World Will Permanently Exceed 1.5°C Tipping Point Before 2030 – At Current Carbon Emissions Rate 05/06/2024 Elaine Ruth Fletcher World reaches record high for annual temperatures over past 12 months – as 1.5°C tipping point approaches. ‘Extortion level’ capital costs put renewables out of reach in most developing economies; fossil fuel companies rake in record profits; and world reels from record heat, freak floods and drought, says UN Secretary General. New climate data released Wednesday shows virtually all key global warming parameters, including land and sea temperatures at all time record high levels for May, as well as for the past year. There’s an 80% likelihood that in at least one of the next five years, the world will temporarily exceed the 1.5°C limit set by the 2015 Paris agreement, said the World Metereological Organization. And at current emissions rates, the world will permanently breach the 1.5° C limit before 2030, warned UN Secretary General Antonio Guterres in a stark message on climate change, coinciding with World Environment Day. “New data from leading climate scientists released today shows the remaining carbon budget to limit long term warning to 1.5 C is now around 200 billion tons – that is the maximum amount of carbon dioxide that the Earth’s atmosphere can take – if we are to have a fighting chance of staying within the limits,” Guterres said. His comments were based on projections released today by WMO and the European Union’s Copernicus climate observatory. “And the truth is, we are burning through the budget at reckless speed, spewing out around 40 billion tons of carbon dioxide a year,” he said urging people “to do the math.” “At this rate, the entire carbon budget will be passed before 2030,” he said in an address was delivered from New York City’s Museum of Natural History – to underline the point that the human species, like dinosaurs, faces a real extinction threat. World’s carbon ‘budget’ surpassed before 2030 UN Secretary General delivers a major address on climate Wednesday 5 June. To avoid permanently breaching the 1.5°C tipping point, global emissions need to fall by 9% every year until 2030, he said. “But they are heading in the wrong direction. Last year, they rose by 1%. “Almost 10 years since the Paris Agreement was adopted, the target of limiting long term global warming to 1.5 degrees Celsius is hanging by a thread. Meanwhile, the godfathers of climate chaos, the fossil fuel industry, rake in record profits supported by a system of trillions [of dollars] in taxpayer funded subsidies.” ‘Extortion-level’ capital costs put green energy out of reach in developing countries Hospital in Johannesburg, South Africa with solar panels: Investments in African renewables was a woeful 1% even as costs globally tumble. It is money that is driving the world to “climate hell”, the UN Secretary General said, calling for a broad overhaul of finance priorities amongst G20 and G7 countries, as well as in private banks and multilaterals. Investments in African renewables represent just 1% of the world’s installed PV solar capacity – while oil and gas profiteers rake the continent for fossil fuels, he noted, citing recent data from the International Energy Agency. “Extortion level capital costs are putting renewables virtually out of reach for most developing and emerging economies – astoundingly and despite the renewables boom of recent years,” Guterres declared. “Clean energy investments in developed developing and emerging economies outside of China have been stuck at the same levels since 2015. Last year, just 15% of new clean energy investment went to emerging markets and developing economies outside China, countries representing nearly two thirds of the world’s population. “And Africa was less than 1% of [PV solar] installations – despite its wealth of natural resources, and vast renewables potential.” All that is coming at a time when globally, clean energy investments reached a record high last year, with wind and solar power growing faster than any other electricity source in developed economies, he noted. Hottest month and year on record Record high sea temperatures are changing ocean and air currents, bleaching corals, threatening ice caps – all accelerating the approach of climate tipping points. May 2024 also was the hottest day in recorded history – marking 12 consecutive months of the hottest weather for the planet ever on record, Guterres noted, citing the fallout that is also being felt from Delhi to the Americas – in terms of record temperatures on the Indian subcontinent, and fierce, unpredictable storms and flooding in southern Brazil. The new WMO report, also released Wednesday, backs that up with detailed data on the unprecedented levels of temperature rise on land as well as on the seas. The WMO report was led by the UK Met Service. Further data on global warming trends was released by the European Union’s Copernicus Climate Service. Based on that data, the global average temperature for the last 12 months (June 2023 – May 2024) is the highest ever on record, at 1.63°C above the 1850–1900 pre-industrial average. And crossing 1.5°C is not merely a matter of crossing a political target, Guterres stressed. “Scientists have alerted us that temperatures rising higher would likely mean the collapse of the Greenland Ice Sheet and the West Antarctic Ice Sheet with catastrophic sea level rise,” he said, And not only that, but also the “destruction of tropical coral reef systems and livelihoods of 300 million people; the collapse of the Labrador Sea currents that would further disrupt weather patterns in Europe; and widespread permafrost melt that will release devastating levels of methane – one of the most potent heat trapping gasses.” Health effects increasingly evident – impacting the poorest and vulnerable Water shortage in Ethiopia. Droughts, flooding and heat waves all create acute health impacts, as well as exacerbating chronic diseases, like cardiovascular disease. Even today, as humankind pushes planetary boundaries to the brink- shattering global temperature records are being recorded around the world, he pointed out. “Already the brutal heatwave has baked Asia with record temperatures, shriveling crops, closing schools and killing people. Cities from New Delhi to Bamako to Mexico City are scorching. Here in the West severe storms have destroyed communities and lives. “We have seen drought and disaster declared across southern Africa and extreme rains flood the Arabian Peninsula, East Africa and Brazil. “And the mass global coral bleaching caused by unprecedented ocean temperatures – soaring past the worst predictions of scientists,” he said, noting that the cost of climate “chaos” could rise to at least $30 trillion by 2050.” And while the rich can huddle inside air conditioned bubbles, at least much of the time, those least responsible for the crisis bear its brunt, he noted. “Extreme events turbocharged by climate change are piling up – destroying lives, families’ economies and hammering health, wracking sustainable development, forcing people from their homes and rocking the foundations of peace and security as people are displaced and vital resources are depleted.” Appeal to G7 and G20 to fix broken financial system ‘Better, bigger and bolder’ commitments to green energy needed from multilateral development banks. To reverse current trends, Guterres called on world leaders, and particularly G7 leaders meeting nexxt week in Italy, as well as the G20, in Rio in November, to commit to ending coal production by 2030 and reduce oil and gas production by 60% – as compared to trillions in fossil fuel subsidies. The world’s leading economies also should: Set up a “high integrity” system for carbon taxes and markets; Relieve the debt burden in developing economies so that investment can flow into green forms of energy; Commit to finally filling the coffers of the Green Energy Fund, with the $100 billion in funds agreed to in previous Climate Conferences, for developing countries. He appealed to private financial institutions to stop funding coal, oil and gas projects – while the G7 and G20 countries should use their influence with multilateral development banks to make “better, bigger and bolder” commitments to green energy infrastructure. “The International Energy Agency reports that clean energy investments in developing and emerging economies beyond China need to reach up to $1.7 trillion a year by the early 2030s. “In short, we need a massive expansion of affordable problem to public and private finance to fuel ambitious new climate plans and deliver clean, affordable energy for all,” he said, pointing to the UN Summit of the Future planned for September “to push reform of the international financial architecture.” Meanwhile, private financial institutions should stop “”bankrolling fossil fuel destruction and start investing in a global renewable revolution,” while shareholders press for disclosure of engagements on fossil fuel multinationals – which have pressed on the gas, rather than releasing the pedal, investing a mere 2.5% in renewable projects, on average last year. Ban advertising of ‘unhealthy’ fossil fuels, as with tobacco Fossil fuels kill, like tobacco. Business and government leaders, moveover, need to confront disinformation and “greenwashing” by the fossil fuel industry, more aggressively. “Many governments restrict or prohibit advertising for products that are dangerous to human health like tobacco,” he pointed out. Some are now doing the same for fossil fuels. “I urge every country to ban advertising from fossil fuel companies. And I urge news media and tech companies to stop taking fossil fuel advertising. Embrace clean technologies Cycling in Fortaleza, Brazil – the city strengthened its active transport system, which reduces carbon emissions from motor vehicles. Meanwhile, he said, the general public can press on demand-side levers. “All of us can make a difference by embracing clean technology, phasing down fossil fuels in our own lives, and using our power as citizens to push for systemic change in the fight for a Livable Future. “People everywhere are far ahead of politicians. Make your voices and your choices count your friends. We do have a choice, creating tipping points for climate progress or gaining tipping points for climate disaster.” Image Credits: World Metereological Organization, Health Care Without Harm , WMO , Oxfam East Africa, WHO FCTC, City of Fortaleza. Strengthening Our Response to Malaria and Neglected Tropical Diseases in a Warming World 05/06/2024 Ibrahima Socé Fall & Michael Adelkunle Charles These children from Savai’i Island, Samoa, are protected by a mosquito net while they sleep. Climate change is perhaps the greatest threat to human health. In a warming world, with changing and unpredictable weather patterns, its effects are all around us. In 2022, Pakistan experienced the worst floods in the country’s history, placing much of the country under water and giving way to a fivefold increase in the country’s rate of malaria transmission. Earlier this year, Brazil declared a state of emergency as its national healthcare system buckled under the pressures of an outbreak of dengue, a neglected tropical disease (NTD) carried by mosquitoes. Cases continue to rise and the outbreak shows no sign of stopping. But Brazil is not alone. Over the past two decades, dengue cases have increased eightfold, with the mosquitoes that carry it thriving in areas where climate change has made temperatures higher and precipitation more abundant. Despite these daily reminders, there is much we do not understand about the impact climate change is exacting on malaria and NTDs, both of which disproportionately impact low-income countries (LICs). An ongoing effort to rid the world of these debilitating diseases by understanding the impacts of climate change isn’t just important – it’s imperative. Evidence gaps An unprecedented scoping review highlights significant gaps in evidence. It was conducted by the World Health Organization (WHO) Task Team on Climate Change, NTDs and Malaria, in partnership with Reaching the Last Mile, a portfolio of global health initiatives driven by the philanthropy of United Arab Emirates President Sheikh Mohamed bin Zayed Al Nahyan. Spanning 42,693 articles from the past decade, the review correlates climate fluctuations with changing disease patterns, confirming that changing temperature and rainfall patterns will shift the transmission windows and geographies of malaria, dengue and chikungunya. The research also reveals that, as our planet warms, the poorest and most vulnerable communities are poised to suffer even more. It also highlights that our research agenda is imbalanced, with studies historically focused on where disease burden is low and access to quality healthcare is high. This is not merely a health issue but a profound injustice that compounds vulnerabilities among those least equipped to bear them. Given the complex and nonlinear ways these diseases interact with changing climates, the importance of closing our gap in understanding is clear. As we already see with dengue in Brazil – and will continue to see in other areas for years to come – diseases are being transmitted faster and farther than before as vectors like mosquitoes expand to regions previously unexposed to these diseases. This could lead to new outbreaks in populations without any natural resistance or existing health infrastructure to manage such diseases. It’s only further complicated by increased displacement and migration as a result of a changing climate. Adaptation and mitigation Health officials speak to community members in Tana River County, Kenya, about the ongoing oral cholera vaccination campaign. Despite the clear risk, our understanding of how to mitigate or adapt to the impact of climate change on malaria and NTDs is limited. Adaptation and mitigation strategies were discussed in only a fraction of the scientific literature reviewed by the WHO Task Team. This needs to change. A new research agenda is crucial to inform evidence-based adaptation and mitigation strategies. In a world acutely aware of the effects of climate change, this all matters immensely if we are to preserve our gains and investments. As global citizens and stakeholders in global health – whether policymakers or researchers, NGOs, funders, or community leaders— we must adapt our strategies and responses not just to the diseases as we’ve known them, but to how they will evolve in a changing climate. This will require innovative approaches to our public health interventions as dynamic as the challenges they aim to counter. We must build resilient, climate-responsive health systems, surveillance programs and intervention strategies to mitigate against or adapt to the immediate-short-term and long-term effects of climate change on malaria and NTDs. We must ensure communities have the resources to respond to health threats in the context of real-time challenges and changing dynamics, like rising temperatures, extended rainy seasons or drought – particularly in the ‘last mile.’ This will require us to reimagine and invest in a new research agenda driven by scientists on the frontlines of this climate-vector-borne disease nexus aimed at protecting those most vulnerable to its impact. Stronger action on the ground We need a committed, global push for research that not only tracks disease trends but actively explores robust intervention strategies that consider the full spectrum of climate impacts. This includes a holistic approach to hazard assessment, driven by research that examines the links between hazards, vulnerability and exposure so we can more accurately project the potential effects of climate change on malaria and NTDs. The climate crisis will only continue to put strain and pressure on already fragile health systems, diverting precious resources from other budget lines, including malaria and NTDs. With more evidence, we can break this cycle and protect the resources needed for disease response. Last week, the World Health Assembly adopted the WHO’s 14th Global Programme of Work, which prioritises the climate-health nexus. Member states also adopted the strongest resolution yet on climate change and health. Now we need to see even stronger action on the ground. Let’s marshal our collective resources and ingenuity to ensure that our responses are as adaptable as the diseases we’re striving to overcome. The time to act is now. This new WHO paper is not just a summary of data; it’s a call to action. It’s a directive for all of us involved in the fight against malaria and NTDs to look beyond our current horizons and plan for a future where climate change reshapes the landscape of global health. For the sake of the millions at risk, we must heed this call and act swiftly and decisively. It’s no small challenge, but one that we can overcome together. Dr Ibrahima Socé Fall is the Director of WHO’s Global NTD Programme. Dr Michael Adelkunle Charles is CEO of the RBM Partnership to End Malaria. Image Credits: Yoshi Shimizu, Billy Miaron/ WHO. WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Global Leaders Appeal for More Resources Ahead of UN meeting on Antimicrobial Resistance 06/06/2024 Kerry Cullinan Drug-resistant bacteria have developed from years of over-prescription of antibiotics. With less than four months to the United Nations High-Level Meeting (HLM) on Antimicrobial Resistance (AMR), global leaders have proposed a variety of measures to address the growing threat of pathogens that are resistant to antibiotics. The recently published zero draft of the political declaration for the meeting aims to reduce global deaths caused by bacterial AMR by 10% by 2030 (using 2019 as the baseline). Mia Mottley, Prime Minister of Barbados and chairperson of the Global Leaders Group on AMR, called for “adequate, predictable and sustainable financing” to address the problem, including financing for research and development for new antibiotics and the implementation of national action plans on AMR, especially in low- and middle-income countries. “Fundamentally, we must focus on prevention across all sectors – clean water, safe and effective sanitation, food security, infection prevention and control in all settings,” Mottley told a lunchtime roundtable during last week’s World Health Assembly. Prime Minister of Barbados Mia Mottley, who chairs the Global Leaders Group on AMR “I believe that we should establish an independent panel to monitor and report on the science and the evidence to facilitate collaborative and coordinated action against AMR,” She also called for the quadripartite joint secretariat on AMR to be formalised and adequately resourced. This is made up of the World Health Organization (WHO), the UN Food and Agriculture Organisation (FAO), UN Environment Programme (UNEP), and the World Organisation for Animal Health (WOAH). The agricultural sector is responsible for the vast majority of antibiotic overuse, leading to drug resistance. Threatens to ‘unwind century of medical progress’ “In 2019, 1.3 million deaths resulted directly from bacterial AMR, more than two every minute,” WHO Director-General Dr Tedros Adhanom Ghebreyesus told the meeting. “AMR threatens to unwind the century of medical progress and also threatens animal health, global food production, food security, and the environment.” Dr Jean Kaseya, Director-General of Africa CDC, noted over one million deaths in Africa were associated with AMR and 250,000 caused by ARM. “Only 1.3% of our labs in Africa are able to perform bacterial resistance testing. It means this data that I’m sharing with you is an underrepresentation of the reality in Africa,” said Kaseya. Four years ago, the African Union Assembly established a task force to control AMR and recommended that all member states implement national action plans. “But less than 10% of a member states have national action plans that are fully funded and implemented,” he added. Kaseya appealed to The Global Fund to expand its mandate from HIV, TB, and malaria to include AMR. Professor Sally Davies, UK Special Envoy on AMR Professor Sally Davies, the UK Special Envoy on AMR and a member of the Global Leaders Group, called for the high-level meeting to “truly address the needs of the most vulnerable communities, offering clear support to low and middle-income countries” that carry the greatest burden of this antibiotic emergency and need fair and equitable access to antibiotics and diagnostics. Surviving AMR Vanessa Carter developed a drug-resistant infection after a car crash cost her an eye. South African Vanessa Carter, chair of WHO Taskforce of AMR Survivors, shared her nightmare of being unable to shake an infection after being seriously injured in a car crash in Johannesburg and losing her right eye. The infection turned out to be the drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA). Hospital patients, people with wounds, and those who have surgery and medical devices implanted in their bodies are particularly at risk of MRSA. Today, I was privileged to share my lived experience of #AMR at the #WHA77 & talk about the work we have already achieved with the @WHO Task Force of AMR Survivors since its inaugural meeting in October 2023 Patients, carers & survivors help to demonstrate the real-world impact… pic.twitter.com/k9onObOpm5 — Vanessa Carter 🇬🇧🇿🇦 (@_FaceSA) May 31, 2024 Carter, who spent a month in hospital, had a prosthetic eye inserted and a number of surgeries. “In my sixth year of surgeries, and my fourth prosthetic [eye], I went out shopping one day, I came back to the car and I felt moisture on my face. When I pulled down the rearview mirror, I saw this pus seeping out of the cheek of the prosthetic,” Carter told the roundtable meeting. Her doctor told her she needed emergency surgery, but two weeks’ later the infection came back again. “I was under the care of different types of specialists, an ENT surgeon, ophthalmologist, plastic surgeon, maxillofacial surgeon, each of them prescribing antibiotics during surgeries,” she added. After almost a year of continued infections, doctors removed the prosthetic eye and sent it for testing and it was found to be contaminated with MRSA. What followed was a long and harrowing process during which the infection got into Carter’s bones before she was finally cured. “I’ve been an advocate for the last 11 years and, most recently, we’ve established the WHO Task Force of AMR Survivors,” said Carter. “Our biggest objective is to bring the human impact. When policy makers and members of the public understand exactly what it is, we can we can empower them. One of the documents we have worked on is a strategic technical guidance document for meaningful patient involvement. I would encourage you to go take a look at it.” World Will Permanently Exceed 1.5°C Tipping Point Before 2030 – At Current Carbon Emissions Rate 05/06/2024 Elaine Ruth Fletcher World reaches record high for annual temperatures over past 12 months – as 1.5°C tipping point approaches. ‘Extortion level’ capital costs put renewables out of reach in most developing economies; fossil fuel companies rake in record profits; and world reels from record heat, freak floods and drought, says UN Secretary General. New climate data released Wednesday shows virtually all key global warming parameters, including land and sea temperatures at all time record high levels for May, as well as for the past year. There’s an 80% likelihood that in at least one of the next five years, the world will temporarily exceed the 1.5°C limit set by the 2015 Paris agreement, said the World Metereological Organization. And at current emissions rates, the world will permanently breach the 1.5° C limit before 2030, warned UN Secretary General Antonio Guterres in a stark message on climate change, coinciding with World Environment Day. “New data from leading climate scientists released today shows the remaining carbon budget to limit long term warning to 1.5 C is now around 200 billion tons – that is the maximum amount of carbon dioxide that the Earth’s atmosphere can take – if we are to have a fighting chance of staying within the limits,” Guterres said. His comments were based on projections released today by WMO and the European Union’s Copernicus climate observatory. “And the truth is, we are burning through the budget at reckless speed, spewing out around 40 billion tons of carbon dioxide a year,” he said urging people “to do the math.” “At this rate, the entire carbon budget will be passed before 2030,” he said in an address was delivered from New York City’s Museum of Natural History – to underline the point that the human species, like dinosaurs, faces a real extinction threat. World’s carbon ‘budget’ surpassed before 2030 UN Secretary General delivers a major address on climate Wednesday 5 June. To avoid permanently breaching the 1.5°C tipping point, global emissions need to fall by 9% every year until 2030, he said. “But they are heading in the wrong direction. Last year, they rose by 1%. “Almost 10 years since the Paris Agreement was adopted, the target of limiting long term global warming to 1.5 degrees Celsius is hanging by a thread. Meanwhile, the godfathers of climate chaos, the fossil fuel industry, rake in record profits supported by a system of trillions [of dollars] in taxpayer funded subsidies.” ‘Extortion-level’ capital costs put green energy out of reach in developing countries Hospital in Johannesburg, South Africa with solar panels: Investments in African renewables was a woeful 1% even as costs globally tumble. It is money that is driving the world to “climate hell”, the UN Secretary General said, calling for a broad overhaul of finance priorities amongst G20 and G7 countries, as well as in private banks and multilaterals. Investments in African renewables represent just 1% of the world’s installed PV solar capacity – while oil and gas profiteers rake the continent for fossil fuels, he noted, citing recent data from the International Energy Agency. “Extortion level capital costs are putting renewables virtually out of reach for most developing and emerging economies – astoundingly and despite the renewables boom of recent years,” Guterres declared. “Clean energy investments in developed developing and emerging economies outside of China have been stuck at the same levels since 2015. Last year, just 15% of new clean energy investment went to emerging markets and developing economies outside China, countries representing nearly two thirds of the world’s population. “And Africa was less than 1% of [PV solar] installations – despite its wealth of natural resources, and vast renewables potential.” All that is coming at a time when globally, clean energy investments reached a record high last year, with wind and solar power growing faster than any other electricity source in developed economies, he noted. Hottest month and year on record Record high sea temperatures are changing ocean and air currents, bleaching corals, threatening ice caps – all accelerating the approach of climate tipping points. May 2024 also was the hottest day in recorded history – marking 12 consecutive months of the hottest weather for the planet ever on record, Guterres noted, citing the fallout that is also being felt from Delhi to the Americas – in terms of record temperatures on the Indian subcontinent, and fierce, unpredictable storms and flooding in southern Brazil. The new WMO report, also released Wednesday, backs that up with detailed data on the unprecedented levels of temperature rise on land as well as on the seas. The WMO report was led by the UK Met Service. Further data on global warming trends was released by the European Union’s Copernicus Climate Service. Based on that data, the global average temperature for the last 12 months (June 2023 – May 2024) is the highest ever on record, at 1.63°C above the 1850–1900 pre-industrial average. And crossing 1.5°C is not merely a matter of crossing a political target, Guterres stressed. “Scientists have alerted us that temperatures rising higher would likely mean the collapse of the Greenland Ice Sheet and the West Antarctic Ice Sheet with catastrophic sea level rise,” he said, And not only that, but also the “destruction of tropical coral reef systems and livelihoods of 300 million people; the collapse of the Labrador Sea currents that would further disrupt weather patterns in Europe; and widespread permafrost melt that will release devastating levels of methane – one of the most potent heat trapping gasses.” Health effects increasingly evident – impacting the poorest and vulnerable Water shortage in Ethiopia. Droughts, flooding and heat waves all create acute health impacts, as well as exacerbating chronic diseases, like cardiovascular disease. Even today, as humankind pushes planetary boundaries to the brink- shattering global temperature records are being recorded around the world, he pointed out. “Already the brutal heatwave has baked Asia with record temperatures, shriveling crops, closing schools and killing people. Cities from New Delhi to Bamako to Mexico City are scorching. Here in the West severe storms have destroyed communities and lives. “We have seen drought and disaster declared across southern Africa and extreme rains flood the Arabian Peninsula, East Africa and Brazil. “And the mass global coral bleaching caused by unprecedented ocean temperatures – soaring past the worst predictions of scientists,” he said, noting that the cost of climate “chaos” could rise to at least $30 trillion by 2050.” And while the rich can huddle inside air conditioned bubbles, at least much of the time, those least responsible for the crisis bear its brunt, he noted. “Extreme events turbocharged by climate change are piling up – destroying lives, families’ economies and hammering health, wracking sustainable development, forcing people from their homes and rocking the foundations of peace and security as people are displaced and vital resources are depleted.” Appeal to G7 and G20 to fix broken financial system ‘Better, bigger and bolder’ commitments to green energy needed from multilateral development banks. To reverse current trends, Guterres called on world leaders, and particularly G7 leaders meeting nexxt week in Italy, as well as the G20, in Rio in November, to commit to ending coal production by 2030 and reduce oil and gas production by 60% – as compared to trillions in fossil fuel subsidies. The world’s leading economies also should: Set up a “high integrity” system for carbon taxes and markets; Relieve the debt burden in developing economies so that investment can flow into green forms of energy; Commit to finally filling the coffers of the Green Energy Fund, with the $100 billion in funds agreed to in previous Climate Conferences, for developing countries. He appealed to private financial institutions to stop funding coal, oil and gas projects – while the G7 and G20 countries should use their influence with multilateral development banks to make “better, bigger and bolder” commitments to green energy infrastructure. “The International Energy Agency reports that clean energy investments in developing and emerging economies beyond China need to reach up to $1.7 trillion a year by the early 2030s. “In short, we need a massive expansion of affordable problem to public and private finance to fuel ambitious new climate plans and deliver clean, affordable energy for all,” he said, pointing to the UN Summit of the Future planned for September “to push reform of the international financial architecture.” Meanwhile, private financial institutions should stop “”bankrolling fossil fuel destruction and start investing in a global renewable revolution,” while shareholders press for disclosure of engagements on fossil fuel multinationals – which have pressed on the gas, rather than releasing the pedal, investing a mere 2.5% in renewable projects, on average last year. Ban advertising of ‘unhealthy’ fossil fuels, as with tobacco Fossil fuels kill, like tobacco. Business and government leaders, moveover, need to confront disinformation and “greenwashing” by the fossil fuel industry, more aggressively. “Many governments restrict or prohibit advertising for products that are dangerous to human health like tobacco,” he pointed out. Some are now doing the same for fossil fuels. “I urge every country to ban advertising from fossil fuel companies. And I urge news media and tech companies to stop taking fossil fuel advertising. Embrace clean technologies Cycling in Fortaleza, Brazil – the city strengthened its active transport system, which reduces carbon emissions from motor vehicles. Meanwhile, he said, the general public can press on demand-side levers. “All of us can make a difference by embracing clean technology, phasing down fossil fuels in our own lives, and using our power as citizens to push for systemic change in the fight for a Livable Future. “People everywhere are far ahead of politicians. Make your voices and your choices count your friends. We do have a choice, creating tipping points for climate progress or gaining tipping points for climate disaster.” Image Credits: World Metereological Organization, Health Care Without Harm , WMO , Oxfam East Africa, WHO FCTC, City of Fortaleza. Strengthening Our Response to Malaria and Neglected Tropical Diseases in a Warming World 05/06/2024 Ibrahima Socé Fall & Michael Adelkunle Charles These children from Savai’i Island, Samoa, are protected by a mosquito net while they sleep. Climate change is perhaps the greatest threat to human health. In a warming world, with changing and unpredictable weather patterns, its effects are all around us. In 2022, Pakistan experienced the worst floods in the country’s history, placing much of the country under water and giving way to a fivefold increase in the country’s rate of malaria transmission. Earlier this year, Brazil declared a state of emergency as its national healthcare system buckled under the pressures of an outbreak of dengue, a neglected tropical disease (NTD) carried by mosquitoes. Cases continue to rise and the outbreak shows no sign of stopping. But Brazil is not alone. Over the past two decades, dengue cases have increased eightfold, with the mosquitoes that carry it thriving in areas where climate change has made temperatures higher and precipitation more abundant. Despite these daily reminders, there is much we do not understand about the impact climate change is exacting on malaria and NTDs, both of which disproportionately impact low-income countries (LICs). An ongoing effort to rid the world of these debilitating diseases by understanding the impacts of climate change isn’t just important – it’s imperative. Evidence gaps An unprecedented scoping review highlights significant gaps in evidence. It was conducted by the World Health Organization (WHO) Task Team on Climate Change, NTDs and Malaria, in partnership with Reaching the Last Mile, a portfolio of global health initiatives driven by the philanthropy of United Arab Emirates President Sheikh Mohamed bin Zayed Al Nahyan. Spanning 42,693 articles from the past decade, the review correlates climate fluctuations with changing disease patterns, confirming that changing temperature and rainfall patterns will shift the transmission windows and geographies of malaria, dengue and chikungunya. The research also reveals that, as our planet warms, the poorest and most vulnerable communities are poised to suffer even more. It also highlights that our research agenda is imbalanced, with studies historically focused on where disease burden is low and access to quality healthcare is high. This is not merely a health issue but a profound injustice that compounds vulnerabilities among those least equipped to bear them. Given the complex and nonlinear ways these diseases interact with changing climates, the importance of closing our gap in understanding is clear. As we already see with dengue in Brazil – and will continue to see in other areas for years to come – diseases are being transmitted faster and farther than before as vectors like mosquitoes expand to regions previously unexposed to these diseases. This could lead to new outbreaks in populations without any natural resistance or existing health infrastructure to manage such diseases. It’s only further complicated by increased displacement and migration as a result of a changing climate. Adaptation and mitigation Health officials speak to community members in Tana River County, Kenya, about the ongoing oral cholera vaccination campaign. Despite the clear risk, our understanding of how to mitigate or adapt to the impact of climate change on malaria and NTDs is limited. Adaptation and mitigation strategies were discussed in only a fraction of the scientific literature reviewed by the WHO Task Team. This needs to change. A new research agenda is crucial to inform evidence-based adaptation and mitigation strategies. In a world acutely aware of the effects of climate change, this all matters immensely if we are to preserve our gains and investments. As global citizens and stakeholders in global health – whether policymakers or researchers, NGOs, funders, or community leaders— we must adapt our strategies and responses not just to the diseases as we’ve known them, but to how they will evolve in a changing climate. This will require innovative approaches to our public health interventions as dynamic as the challenges they aim to counter. We must build resilient, climate-responsive health systems, surveillance programs and intervention strategies to mitigate against or adapt to the immediate-short-term and long-term effects of climate change on malaria and NTDs. We must ensure communities have the resources to respond to health threats in the context of real-time challenges and changing dynamics, like rising temperatures, extended rainy seasons or drought – particularly in the ‘last mile.’ This will require us to reimagine and invest in a new research agenda driven by scientists on the frontlines of this climate-vector-borne disease nexus aimed at protecting those most vulnerable to its impact. Stronger action on the ground We need a committed, global push for research that not only tracks disease trends but actively explores robust intervention strategies that consider the full spectrum of climate impacts. This includes a holistic approach to hazard assessment, driven by research that examines the links between hazards, vulnerability and exposure so we can more accurately project the potential effects of climate change on malaria and NTDs. The climate crisis will only continue to put strain and pressure on already fragile health systems, diverting precious resources from other budget lines, including malaria and NTDs. With more evidence, we can break this cycle and protect the resources needed for disease response. Last week, the World Health Assembly adopted the WHO’s 14th Global Programme of Work, which prioritises the climate-health nexus. Member states also adopted the strongest resolution yet on climate change and health. Now we need to see even stronger action on the ground. Let’s marshal our collective resources and ingenuity to ensure that our responses are as adaptable as the diseases we’re striving to overcome. The time to act is now. This new WHO paper is not just a summary of data; it’s a call to action. It’s a directive for all of us involved in the fight against malaria and NTDs to look beyond our current horizons and plan for a future where climate change reshapes the landscape of global health. For the sake of the millions at risk, we must heed this call and act swiftly and decisively. It’s no small challenge, but one that we can overcome together. Dr Ibrahima Socé Fall is the Director of WHO’s Global NTD Programme. Dr Michael Adelkunle Charles is CEO of the RBM Partnership to End Malaria. Image Credits: Yoshi Shimizu, Billy Miaron/ WHO. WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
World Will Permanently Exceed 1.5°C Tipping Point Before 2030 – At Current Carbon Emissions Rate 05/06/2024 Elaine Ruth Fletcher World reaches record high for annual temperatures over past 12 months – as 1.5°C tipping point approaches. ‘Extortion level’ capital costs put renewables out of reach in most developing economies; fossil fuel companies rake in record profits; and world reels from record heat, freak floods and drought, says UN Secretary General. New climate data released Wednesday shows virtually all key global warming parameters, including land and sea temperatures at all time record high levels for May, as well as for the past year. There’s an 80% likelihood that in at least one of the next five years, the world will temporarily exceed the 1.5°C limit set by the 2015 Paris agreement, said the World Metereological Organization. And at current emissions rates, the world will permanently breach the 1.5° C limit before 2030, warned UN Secretary General Antonio Guterres in a stark message on climate change, coinciding with World Environment Day. “New data from leading climate scientists released today shows the remaining carbon budget to limit long term warning to 1.5 C is now around 200 billion tons – that is the maximum amount of carbon dioxide that the Earth’s atmosphere can take – if we are to have a fighting chance of staying within the limits,” Guterres said. His comments were based on projections released today by WMO and the European Union’s Copernicus climate observatory. “And the truth is, we are burning through the budget at reckless speed, spewing out around 40 billion tons of carbon dioxide a year,” he said urging people “to do the math.” “At this rate, the entire carbon budget will be passed before 2030,” he said in an address was delivered from New York City’s Museum of Natural History – to underline the point that the human species, like dinosaurs, faces a real extinction threat. World’s carbon ‘budget’ surpassed before 2030 UN Secretary General delivers a major address on climate Wednesday 5 June. To avoid permanently breaching the 1.5°C tipping point, global emissions need to fall by 9% every year until 2030, he said. “But they are heading in the wrong direction. Last year, they rose by 1%. “Almost 10 years since the Paris Agreement was adopted, the target of limiting long term global warming to 1.5 degrees Celsius is hanging by a thread. Meanwhile, the godfathers of climate chaos, the fossil fuel industry, rake in record profits supported by a system of trillions [of dollars] in taxpayer funded subsidies.” ‘Extortion-level’ capital costs put green energy out of reach in developing countries Hospital in Johannesburg, South Africa with solar panels: Investments in African renewables was a woeful 1% even as costs globally tumble. It is money that is driving the world to “climate hell”, the UN Secretary General said, calling for a broad overhaul of finance priorities amongst G20 and G7 countries, as well as in private banks and multilaterals. Investments in African renewables represent just 1% of the world’s installed PV solar capacity – while oil and gas profiteers rake the continent for fossil fuels, he noted, citing recent data from the International Energy Agency. “Extortion level capital costs are putting renewables virtually out of reach for most developing and emerging economies – astoundingly and despite the renewables boom of recent years,” Guterres declared. “Clean energy investments in developed developing and emerging economies outside of China have been stuck at the same levels since 2015. Last year, just 15% of new clean energy investment went to emerging markets and developing economies outside China, countries representing nearly two thirds of the world’s population. “And Africa was less than 1% of [PV solar] installations – despite its wealth of natural resources, and vast renewables potential.” All that is coming at a time when globally, clean energy investments reached a record high last year, with wind and solar power growing faster than any other electricity source in developed economies, he noted. Hottest month and year on record Record high sea temperatures are changing ocean and air currents, bleaching corals, threatening ice caps – all accelerating the approach of climate tipping points. May 2024 also was the hottest day in recorded history – marking 12 consecutive months of the hottest weather for the planet ever on record, Guterres noted, citing the fallout that is also being felt from Delhi to the Americas – in terms of record temperatures on the Indian subcontinent, and fierce, unpredictable storms and flooding in southern Brazil. The new WMO report, also released Wednesday, backs that up with detailed data on the unprecedented levels of temperature rise on land as well as on the seas. The WMO report was led by the UK Met Service. Further data on global warming trends was released by the European Union’s Copernicus Climate Service. Based on that data, the global average temperature for the last 12 months (June 2023 – May 2024) is the highest ever on record, at 1.63°C above the 1850–1900 pre-industrial average. And crossing 1.5°C is not merely a matter of crossing a political target, Guterres stressed. “Scientists have alerted us that temperatures rising higher would likely mean the collapse of the Greenland Ice Sheet and the West Antarctic Ice Sheet with catastrophic sea level rise,” he said, And not only that, but also the “destruction of tropical coral reef systems and livelihoods of 300 million people; the collapse of the Labrador Sea currents that would further disrupt weather patterns in Europe; and widespread permafrost melt that will release devastating levels of methane – one of the most potent heat trapping gasses.” Health effects increasingly evident – impacting the poorest and vulnerable Water shortage in Ethiopia. Droughts, flooding and heat waves all create acute health impacts, as well as exacerbating chronic diseases, like cardiovascular disease. Even today, as humankind pushes planetary boundaries to the brink- shattering global temperature records are being recorded around the world, he pointed out. “Already the brutal heatwave has baked Asia with record temperatures, shriveling crops, closing schools and killing people. Cities from New Delhi to Bamako to Mexico City are scorching. Here in the West severe storms have destroyed communities and lives. “We have seen drought and disaster declared across southern Africa and extreme rains flood the Arabian Peninsula, East Africa and Brazil. “And the mass global coral bleaching caused by unprecedented ocean temperatures – soaring past the worst predictions of scientists,” he said, noting that the cost of climate “chaos” could rise to at least $30 trillion by 2050.” And while the rich can huddle inside air conditioned bubbles, at least much of the time, those least responsible for the crisis bear its brunt, he noted. “Extreme events turbocharged by climate change are piling up – destroying lives, families’ economies and hammering health, wracking sustainable development, forcing people from their homes and rocking the foundations of peace and security as people are displaced and vital resources are depleted.” Appeal to G7 and G20 to fix broken financial system ‘Better, bigger and bolder’ commitments to green energy needed from multilateral development banks. To reverse current trends, Guterres called on world leaders, and particularly G7 leaders meeting nexxt week in Italy, as well as the G20, in Rio in November, to commit to ending coal production by 2030 and reduce oil and gas production by 60% – as compared to trillions in fossil fuel subsidies. The world’s leading economies also should: Set up a “high integrity” system for carbon taxes and markets; Relieve the debt burden in developing economies so that investment can flow into green forms of energy; Commit to finally filling the coffers of the Green Energy Fund, with the $100 billion in funds agreed to in previous Climate Conferences, for developing countries. He appealed to private financial institutions to stop funding coal, oil and gas projects – while the G7 and G20 countries should use their influence with multilateral development banks to make “better, bigger and bolder” commitments to green energy infrastructure. “The International Energy Agency reports that clean energy investments in developing and emerging economies beyond China need to reach up to $1.7 trillion a year by the early 2030s. “In short, we need a massive expansion of affordable problem to public and private finance to fuel ambitious new climate plans and deliver clean, affordable energy for all,” he said, pointing to the UN Summit of the Future planned for September “to push reform of the international financial architecture.” Meanwhile, private financial institutions should stop “”bankrolling fossil fuel destruction and start investing in a global renewable revolution,” while shareholders press for disclosure of engagements on fossil fuel multinationals – which have pressed on the gas, rather than releasing the pedal, investing a mere 2.5% in renewable projects, on average last year. Ban advertising of ‘unhealthy’ fossil fuels, as with tobacco Fossil fuels kill, like tobacco. Business and government leaders, moveover, need to confront disinformation and “greenwashing” by the fossil fuel industry, more aggressively. “Many governments restrict or prohibit advertising for products that are dangerous to human health like tobacco,” he pointed out. Some are now doing the same for fossil fuels. “I urge every country to ban advertising from fossil fuel companies. And I urge news media and tech companies to stop taking fossil fuel advertising. Embrace clean technologies Cycling in Fortaleza, Brazil – the city strengthened its active transport system, which reduces carbon emissions from motor vehicles. Meanwhile, he said, the general public can press on demand-side levers. “All of us can make a difference by embracing clean technology, phasing down fossil fuels in our own lives, and using our power as citizens to push for systemic change in the fight for a Livable Future. “People everywhere are far ahead of politicians. Make your voices and your choices count your friends. We do have a choice, creating tipping points for climate progress or gaining tipping points for climate disaster.” Image Credits: World Metereological Organization, Health Care Without Harm , WMO , Oxfam East Africa, WHO FCTC, City of Fortaleza. Strengthening Our Response to Malaria and Neglected Tropical Diseases in a Warming World 05/06/2024 Ibrahima Socé Fall & Michael Adelkunle Charles These children from Savai’i Island, Samoa, are protected by a mosquito net while they sleep. Climate change is perhaps the greatest threat to human health. In a warming world, with changing and unpredictable weather patterns, its effects are all around us. In 2022, Pakistan experienced the worst floods in the country’s history, placing much of the country under water and giving way to a fivefold increase in the country’s rate of malaria transmission. Earlier this year, Brazil declared a state of emergency as its national healthcare system buckled under the pressures of an outbreak of dengue, a neglected tropical disease (NTD) carried by mosquitoes. Cases continue to rise and the outbreak shows no sign of stopping. But Brazil is not alone. Over the past two decades, dengue cases have increased eightfold, with the mosquitoes that carry it thriving in areas where climate change has made temperatures higher and precipitation more abundant. Despite these daily reminders, there is much we do not understand about the impact climate change is exacting on malaria and NTDs, both of which disproportionately impact low-income countries (LICs). An ongoing effort to rid the world of these debilitating diseases by understanding the impacts of climate change isn’t just important – it’s imperative. Evidence gaps An unprecedented scoping review highlights significant gaps in evidence. It was conducted by the World Health Organization (WHO) Task Team on Climate Change, NTDs and Malaria, in partnership with Reaching the Last Mile, a portfolio of global health initiatives driven by the philanthropy of United Arab Emirates President Sheikh Mohamed bin Zayed Al Nahyan. Spanning 42,693 articles from the past decade, the review correlates climate fluctuations with changing disease patterns, confirming that changing temperature and rainfall patterns will shift the transmission windows and geographies of malaria, dengue and chikungunya. The research also reveals that, as our planet warms, the poorest and most vulnerable communities are poised to suffer even more. It also highlights that our research agenda is imbalanced, with studies historically focused on where disease burden is low and access to quality healthcare is high. This is not merely a health issue but a profound injustice that compounds vulnerabilities among those least equipped to bear them. Given the complex and nonlinear ways these diseases interact with changing climates, the importance of closing our gap in understanding is clear. As we already see with dengue in Brazil – and will continue to see in other areas for years to come – diseases are being transmitted faster and farther than before as vectors like mosquitoes expand to regions previously unexposed to these diseases. This could lead to new outbreaks in populations without any natural resistance or existing health infrastructure to manage such diseases. It’s only further complicated by increased displacement and migration as a result of a changing climate. Adaptation and mitigation Health officials speak to community members in Tana River County, Kenya, about the ongoing oral cholera vaccination campaign. Despite the clear risk, our understanding of how to mitigate or adapt to the impact of climate change on malaria and NTDs is limited. Adaptation and mitigation strategies were discussed in only a fraction of the scientific literature reviewed by the WHO Task Team. This needs to change. A new research agenda is crucial to inform evidence-based adaptation and mitigation strategies. In a world acutely aware of the effects of climate change, this all matters immensely if we are to preserve our gains and investments. As global citizens and stakeholders in global health – whether policymakers or researchers, NGOs, funders, or community leaders— we must adapt our strategies and responses not just to the diseases as we’ve known them, but to how they will evolve in a changing climate. This will require innovative approaches to our public health interventions as dynamic as the challenges they aim to counter. We must build resilient, climate-responsive health systems, surveillance programs and intervention strategies to mitigate against or adapt to the immediate-short-term and long-term effects of climate change on malaria and NTDs. We must ensure communities have the resources to respond to health threats in the context of real-time challenges and changing dynamics, like rising temperatures, extended rainy seasons or drought – particularly in the ‘last mile.’ This will require us to reimagine and invest in a new research agenda driven by scientists on the frontlines of this climate-vector-borne disease nexus aimed at protecting those most vulnerable to its impact. Stronger action on the ground We need a committed, global push for research that not only tracks disease trends but actively explores robust intervention strategies that consider the full spectrum of climate impacts. This includes a holistic approach to hazard assessment, driven by research that examines the links between hazards, vulnerability and exposure so we can more accurately project the potential effects of climate change on malaria and NTDs. The climate crisis will only continue to put strain and pressure on already fragile health systems, diverting precious resources from other budget lines, including malaria and NTDs. With more evidence, we can break this cycle and protect the resources needed for disease response. Last week, the World Health Assembly adopted the WHO’s 14th Global Programme of Work, which prioritises the climate-health nexus. Member states also adopted the strongest resolution yet on climate change and health. Now we need to see even stronger action on the ground. Let’s marshal our collective resources and ingenuity to ensure that our responses are as adaptable as the diseases we’re striving to overcome. The time to act is now. This new WHO paper is not just a summary of data; it’s a call to action. It’s a directive for all of us involved in the fight against malaria and NTDs to look beyond our current horizons and plan for a future where climate change reshapes the landscape of global health. For the sake of the millions at risk, we must heed this call and act swiftly and decisively. It’s no small challenge, but one that we can overcome together. Dr Ibrahima Socé Fall is the Director of WHO’s Global NTD Programme. Dr Michael Adelkunle Charles is CEO of the RBM Partnership to End Malaria. Image Credits: Yoshi Shimizu, Billy Miaron/ WHO. WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Strengthening Our Response to Malaria and Neglected Tropical Diseases in a Warming World 05/06/2024 Ibrahima Socé Fall & Michael Adelkunle Charles These children from Savai’i Island, Samoa, are protected by a mosquito net while they sleep. Climate change is perhaps the greatest threat to human health. In a warming world, with changing and unpredictable weather patterns, its effects are all around us. In 2022, Pakistan experienced the worst floods in the country’s history, placing much of the country under water and giving way to a fivefold increase in the country’s rate of malaria transmission. Earlier this year, Brazil declared a state of emergency as its national healthcare system buckled under the pressures of an outbreak of dengue, a neglected tropical disease (NTD) carried by mosquitoes. Cases continue to rise and the outbreak shows no sign of stopping. But Brazil is not alone. Over the past two decades, dengue cases have increased eightfold, with the mosquitoes that carry it thriving in areas where climate change has made temperatures higher and precipitation more abundant. Despite these daily reminders, there is much we do not understand about the impact climate change is exacting on malaria and NTDs, both of which disproportionately impact low-income countries (LICs). An ongoing effort to rid the world of these debilitating diseases by understanding the impacts of climate change isn’t just important – it’s imperative. Evidence gaps An unprecedented scoping review highlights significant gaps in evidence. It was conducted by the World Health Organization (WHO) Task Team on Climate Change, NTDs and Malaria, in partnership with Reaching the Last Mile, a portfolio of global health initiatives driven by the philanthropy of United Arab Emirates President Sheikh Mohamed bin Zayed Al Nahyan. Spanning 42,693 articles from the past decade, the review correlates climate fluctuations with changing disease patterns, confirming that changing temperature and rainfall patterns will shift the transmission windows and geographies of malaria, dengue and chikungunya. The research also reveals that, as our planet warms, the poorest and most vulnerable communities are poised to suffer even more. It also highlights that our research agenda is imbalanced, with studies historically focused on where disease burden is low and access to quality healthcare is high. This is not merely a health issue but a profound injustice that compounds vulnerabilities among those least equipped to bear them. Given the complex and nonlinear ways these diseases interact with changing climates, the importance of closing our gap in understanding is clear. As we already see with dengue in Brazil – and will continue to see in other areas for years to come – diseases are being transmitted faster and farther than before as vectors like mosquitoes expand to regions previously unexposed to these diseases. This could lead to new outbreaks in populations without any natural resistance or existing health infrastructure to manage such diseases. It’s only further complicated by increased displacement and migration as a result of a changing climate. Adaptation and mitigation Health officials speak to community members in Tana River County, Kenya, about the ongoing oral cholera vaccination campaign. Despite the clear risk, our understanding of how to mitigate or adapt to the impact of climate change on malaria and NTDs is limited. Adaptation and mitigation strategies were discussed in only a fraction of the scientific literature reviewed by the WHO Task Team. This needs to change. A new research agenda is crucial to inform evidence-based adaptation and mitigation strategies. In a world acutely aware of the effects of climate change, this all matters immensely if we are to preserve our gains and investments. As global citizens and stakeholders in global health – whether policymakers or researchers, NGOs, funders, or community leaders— we must adapt our strategies and responses not just to the diseases as we’ve known them, but to how they will evolve in a changing climate. This will require innovative approaches to our public health interventions as dynamic as the challenges they aim to counter. We must build resilient, climate-responsive health systems, surveillance programs and intervention strategies to mitigate against or adapt to the immediate-short-term and long-term effects of climate change on malaria and NTDs. We must ensure communities have the resources to respond to health threats in the context of real-time challenges and changing dynamics, like rising temperatures, extended rainy seasons or drought – particularly in the ‘last mile.’ This will require us to reimagine and invest in a new research agenda driven by scientists on the frontlines of this climate-vector-borne disease nexus aimed at protecting those most vulnerable to its impact. Stronger action on the ground We need a committed, global push for research that not only tracks disease trends but actively explores robust intervention strategies that consider the full spectrum of climate impacts. This includes a holistic approach to hazard assessment, driven by research that examines the links between hazards, vulnerability and exposure so we can more accurately project the potential effects of climate change on malaria and NTDs. The climate crisis will only continue to put strain and pressure on already fragile health systems, diverting precious resources from other budget lines, including malaria and NTDs. With more evidence, we can break this cycle and protect the resources needed for disease response. Last week, the World Health Assembly adopted the WHO’s 14th Global Programme of Work, which prioritises the climate-health nexus. Member states also adopted the strongest resolution yet on climate change and health. Now we need to see even stronger action on the ground. Let’s marshal our collective resources and ingenuity to ensure that our responses are as adaptable as the diseases we’re striving to overcome. The time to act is now. This new WHO paper is not just a summary of data; it’s a call to action. It’s a directive for all of us involved in the fight against malaria and NTDs to look beyond our current horizons and plan for a future where climate change reshapes the landscape of global health. For the sake of the millions at risk, we must heed this call and act swiftly and decisively. It’s no small challenge, but one that we can overcome together. Dr Ibrahima Socé Fall is the Director of WHO’s Global NTD Programme. Dr Michael Adelkunle Charles is CEO of the RBM Partnership to End Malaria. Image Credits: Yoshi Shimizu, Billy Miaron/ WHO. WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Executive Board Votes to Recognize Center for Reproductive Rights But Egypt Promises to ‘Escalate’ Issue to WHA 04/06/2024 Elaine Ruth Fletcher Votes to move to a secret ballot broke down along almost the same geopolitical lines – with 14 opponents (voting here) versus 17 supporters. The World Health Organization (WHO) Executive Board on Tuesday voted to recognize the US-based Center for Reproductive Rights (CRR) as a non-state actor “in official relations” with it, in a motion carried by a narrow 17-13 margin, with four abstentions. After multiple rounds of voting, the final vote was by way of a secret ballot. The decision to grant WHO recognition to the Center, which supports access to sexual and reproductive health services, including abortion, was a hard-won victory for European, Asian and Latin American countries. But the victory may be short-lived. Egypt, backed by a coalition of Middle Eastern and Islamic nations, as well as the 47-member WHO African Group, pledged to “escalate” the issue to the World Health Assembly (WHA), a promise that it reaffirmed shortly after the vote in the WHO governing body, calling the vote a “politicization” of the global health body. Egypt’s delegate to the EB (back left) pledges “to pursue” the controversial issue at the World Health Assembly. “We would like to repeat what we have mentioned yesterday,” said Egypt’s delegate. “That we will pursue reopening of the discussions on this agenda item within the wider quorum of the organization during the upcoming WHA”. He added that, at the national level, the decision ” is of no weight… we will not abide by it, and will not consider it in any means”. “Also, we will join the Russian Federation on their query, which is ‘how could we avoid the repetition of such unpleasant situation?’.. We need the good offices of the WHO in order to avoid the politicization of this organization as it has been experienced frequently in the past few days. “ “The text that was adopted today will not be implemented in Senegal, unless it is compatible with our laws, traditions and values,” said Senegal’s delegate, echoing sentiments expressed by Yemen, Kuwait, Somalia, and other member states in the post-vote discussion. National context still prevails The Netherlands: WHO recognition of non-state actors does not commit member states where, “the national context prevails.” Member states that supported the move by the 34-member governing body noted that other nations are in no way obliged to cooperate with the Center, or with any other non-state actor, which they oppose. They stressed that the recognition was being extended solely by the WHO Secretariat, which maintains a wide network of official relations with over 200 non-state actors from civil society, industry federations and professional associations in line with a Framework for Engagement with Non-State Actors (FENSA) approved by the World Health Assembly in 2016. The vote also awarded WHO recognition to a second non-state actor, Rare Diseases International, whose candidacy was never opposed by member states. “The Framework of Engagement with Non State Actors (FENSA) is one of WHO normative guidelines, which has been negotiated and agreed by all member states,” The Netherlands pointed out. “Questioning any non-state actor about its eligibility for admission into an official relationship with WHO after the organization passed the Secretariat’s criteria, undermines a great procedure and sets a harmful precedent for the future agreements. However “the national context prevails over WHO engagements with non state actors,” she emphasized. FENSA framework is supposed to be neutral The FENSA framework sets out a set of generic criteria for organizations “in official relations” to engage in collaborations with WHO, serve on technical groups and be recognized as “observers” with the right to speak at the annual WHA. The aim of FENSA, which took years to negotiate and approve, was to create an even playing field in the much-coveted “official relations” designation that would side-step vested interests, particularly of industry or lobbying groups, that contravened WHO aims and priniciples. Since the approval of FENSA, the handful of recommendations made by WHO each year to the Executive Board, to approve new NSA’s in official relations with WHA, or renew the terms of others, are usually just a matter of protocol, following WHO review and due diligence. But there is growing pressure on the UN from socially conservative nations to roll back its activities on sexual and reproductive health in a period where many conservative nations still ban abortions, limit access to contraceptives and criminalize the LGBTQI community. Proposed WHO Recognition of Center for Reproductive Rights Provokes Storm at WHO Executive Board As member states pointed out, the CRR has long been recognized by the UN’s Economic and Social Council (ECOSOC), highlighting how the controversy over its recognition by WHO is a sign of the times, with intensive pushback not only in major powers such as the US and Russia, but also in international forums against the recognition of reproductive health rights long taken for granted in many societies. Multiple votes are worrisome precedent for WHO governing body Poland pledges to uphold the “consensus” around the FENSA framework for engagement with non-state actors. For the EB members, themselves, the repeated votes, including by secret ballot, was yet another worrisome sign of the growing fracture between WHO member states in Europe, the Americas and Asia, which tend to identify themselves as socially and politically liberal, and developing nations in Africa as well as Russia, and the Middle East – where more conservative worldviews prevail. The result, most member states agree, is the creeping “politicization” of global health agendas and issues. And while everyone also has a different point of view about what is political, it’s clear that it is leading to fewer decisions by consensus and more by lengthy, and often bitter, rounds of votes. “After a record number of votes in the last week, we are alarmed by the notion that this is now becoming the default way to solve difficult issue,” said Poland’s delegate. “We would like to remind everyone that we adopted the FENSA by consensus, and we should respect it subtle equilibrium for the sake of our collective interests. Matthew Wilson (center): “What you did was democracy” “It is essential to preserve the independent, transparent, technical and evidence based role of the World Health Organization. We highly appreciate the efforts of the direct chair and other member states in trying to find a solution we could have all subscribed to. Poland remains committed to decision-making by consensus in this organization, and rejects the notion that the voting is now mainstream. We will spare no effort in supporting effective multilateralism and fostering consensus – with all due respect for different contexts of different countries.” New EB Chair, Matthew Wilson, who sought to strike a more consensual note after the vote, declared: “What you did was democracy, and that’s not a bad thing.” Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Healthy Heart Africa Expands NCD Program to Cover Chronic Kidney Disease 04/06/2024 Editorial team Dr Franklin Asiedu Bekoe, Director Public Health, Ghana Health Service (right) and Dr Winfred Ofosu of Ghana Health Service (right standing) signing an MoU with Deepak Arora, Country President, African Cluster at AstraZeneca (left) and Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit of AstraZeneca (left standing). On the sidelines of the 77th World Health Assembly last week, Healthy Heart Africa announced that it would be expanding its work to tackle the rising burden of non-communicable diseases (NCDs) in Africa. Starting this year, the program – which was launched by AstraZeneca in 2014 initially to address hypertension – will now also support countries in combating chronic kidney disease (CKD) and extend its reach into additional countries in North Africa. We sat down with Deepak Arora, Country President for the African Cluster at AstraZeneca, to learn more about what this expansion means for the continent. Deepak Arora, Country President, African Cluster, AstraZeneca. How has Healthy Heart Africa helped address NCDs across Africa? Partnering with governments, healthcare providers and local communities, AstraZeneca’s Healthy Heart Africa programme supports countries in addressing the growing social and economic burden of NCDs by targeting those in greatest need and improving equitable access to care. The programme aims to challenge traditional thinking and advocate for policy changes in healthcare to improve outcomes for all individuals affected by NCDs, regardless of their demographic, geographic or socio-economic status. It also seeks to support health systems to embrace innovative health technologies, which have the potential to make screening more accessible, particularly in remote and underserved communities in Africa. Since our founding 10 years ago, Healthy Heart Africa has trained more than 11,480 healthcare workers and screened more than 50 million people and achieved its aspiration of identifying over 10 million patients with elevated blood pressure across the continent. To date, HHA has been implemented in Kenya, Ethiopia, Tanzania, Ghana, Nigeria, Uganda, Côte d’Ivoire, Senegal, Rwanda, and now Egypt. We are so proud of this impact. What is the significance of the Memorandums of Understanding (MoU) signed in Uganda and Ghana, and what impact will these have on the countries’ efforts to address the rising burden of NCDs? In Uganda, chronic kidney disease (CKD) is increasing and is among the top 10 causes of death. This growing burden requires a multifaceted approach that incorporates early screening, diagnosis, and treatment at a primary care level. The new MoU that we have signed with the Ministry of Health of Uganda will enable us to expand the Healthy Heart Africa programme in the country to tackle this disease. This includes increased education efforts on the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system; and offering health screening, and access to treatment and disease management. Similarly, in Ghana, the overall prevalence of CKD has been shown to range between 6.74% and 13.3% and is associated with increasing morbidity and mortality, which places significant financial burden on the health system. AstraZeneca’s Healthy Heart Africa programme has been working with the Ministry of Health, Ghana Health Services, and our implementing partner, PATH, to address hypertension and cardiovascular disease in Ghana since 2019. Our shared commitment to address NCDs is reflected in the memorandum of understanding signed with Ghana Health Services. We are expanding the HHA programme to address the growing and unmet need for chronic kidney disease. The expanded scope builds on HHA’s scientific legacy of collaborative partnerships to cardiovascular diseases in Africa. This memorandum of understanding outlines the terms and agreements of engagement and collaboration between HHA and Ghana Health Services in cardiorenal care in Ghana. What unique role does a pharmaceutical company like AstraZeneca play in improving NCD care in Africa? Pharmaceutical companies don’t only develop and provide health products. They also bring a depth of knowledge about the patient care journey, which can provide insights into what prevents people from getting screened and treated and in turn, strengthen health systems. We also have extensive experience bringing together a range of stakeholders to address health challenges – from public health experts, researchers, and patients, to tech firms, government officials, and policymakers. Partnerships are central to the Healthy Heart Africa programme. Working together, we’re able to maximise our impact by addressing the barriers that prevent access to care; increasing awareness of the symptoms and risks of hypertension and educating about healthy lifestyle choices; training providers and driving care to lower levels of the healthcare system, and offering health screening, and access to treatment and disease management. A significant aspect of CKD is its strong interconnection with other non-communicable diseases such as diabetes and hypertension. These conditions often coexist, creating a complex interplay that exacerbates patient outcomes. For instance, a person with diabetes is at higher risk for cardiovascular issues, and vice versa. Globally, the incidence of cardiovascular disease among patients with type 2 diabetes is two to three times higher than among those without type 2 diabetes. Similarly, hypertension can both result from and contribute to the progression of kidney diseases. This interconnection underscores the necessity of integrated healthcare approaches to manage CKD alongside other NCDs. What impact do you hope to have by expanding Healthy Heart Africa? NCDs, including heart and kidney diseases, are rapidly escalating in Africa. All too often, they are underdiagnosed, undertreated and their interconnections are under-recognised, affecting and claiming millions of lives every year. NCDs are also exacerbated by climate change, with extreme heat adding stress to the human body and impairing the function of these vital organs. For instance, the carbon intensity of chronic kidney disease treatments, such as dialysis, contributes significantly to carbon emissions, further stressing the need for sustainable healthcare solutions. The detrimental effects underscore the urgent need to integrate broader health strategies to combat these diseases more effectively. That’s why Healthy Heart Africa is stepping up its efforts. Building on a decade of impact, the programme is tackling the growing burden by broadening its scope to include both heart and kidney diseases. This expansion underscores the importance AstraZeneca places on education and awareness programmes, screening and early diagnosis and sustainable healthcare that aim to improve the resiliency and sustainability of health systems in Africa, and ultimately enhance the well-being of all people across the continent. By prioritizing access to care for underserved populations, the initiative aims to improve the resiliency and sustainability of health systems in Africa, ensuring that everyone, regardless of their socioeconomic status, has the opportunity to achieve better health outcomes and ultimate enhance the well-being of all people across the continent. This Q&A is supported by AstraZeneca Image Credits: Fred Merz. Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Gavi Needs Urgent Reform to Ensure its Continued Impact 04/06/2024 Janeen Madan Keller & Orin Levine A baby gets vaccinated against polio thanks to su With the first-ever malaria vaccines rolling out across Africa and a next-generation tuberculosis (TB) vaccine in testing, scientific advances are driving an unparalleled expansion of vaccine development. But vaccines in development don’t become immunizations that protect our health without concerted efforts by global initiatives like Gavi, the vaccine alliance, that help bring these life-saving products to the world’s poorest countries. Next month, Gavi will kick-off a campaign to raise several billion dollars to deliver on its new strategy. The stakes are high: falling short of its target could delay delivery of vaccines to those most in need. But amidst a rapidly changing global landscape, Gavi’s leadership and board must look inwards and seize the opportunity to reform by adjusting its operational model, addressing how it delivers vaccines in humanitarian and conflict settings, sustaining the impact of its investments, and aligning with other global health initiatives to respond to country priorities. By Gavi’s own count, it has helped immunize more than a billion children since its launch in 2000. But underlying this remarkable impact is a stark reality: millions of women and children continue to miss out on vaccines. Perhaps most staggering is the fact that close to 15 million children around the world still do not receive basic childhood vaccines, leaving the poorest and most vulnerable susceptible to preventable diseases. Significant gaps in accessing newer vaccines also exist. Only 20% of girls worldwide have received the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer. As Gavi’s leadership and board finalize a new strategy that will cement its priorities over the next five years, we urge attention to three areas to ensure that every child, everywhere, has access to vaccines. Rethink criteria for selecting countries First, Gavi should update how it deems which countries receive support. Since its early days, Gavi has channeled financial support for immunization, based on national income per capita, to the poorest countries that also showed the biggest gaps in immunization access. The model is simple: if national income per capita is below the eligibility line, a country can receive full Gavi support; if it is above the line, then no support is given. But almost 25 years later, it’s time to refine how this works. As a growing number of countries face economic headwinds and stagnating vaccination rates in the post-COVID era, Gavi needs to better match support with a country’s ability to pay for vaccines. And as new vaccines – including for TB – become available, Gavi’s model needs to align with the burden of leading infectious killers. As one case in point: four of the highest TB burden countries – India, Indonesia, China, and the Philippines – are no longer or were never eligible for Gavi support. But ironically, they are eligible for financial support for TB diagnosis and treatment from Gavi’s sister organization, The Global Fund for AIDS, TB, and Malaria. This policy mismatch could limit the impact of a new vaccine against a major infectious killer. Invest more in vaccine delivery innovation Second, Gavi should play a bigger role in scaling innovations to address the barriers that deter vaccine delivery. COVID-19 laid bare just how critical health systems infrastructure is to stopping disease outbreaks in their tracks. It also proved how useful innovations like digital immunization records can be in boosting vaccine uptake. With dedicated resources, Gavi can support partner countries to scale proven innovations for immunization systems they want and need. This could include solar panels for electrification of health clinics, unmanned drones for vaccine delivery, and digital immunization records. While each of these innovations has been proven to work, Gavi’s investments would fill a critical gap in providing financing to scale, thereby leveraging at-risk early funding by other partners. Gavi’s track record in innovation, including financing mechanisms to scale new vaccine introductions, makes it well placed to do so. Pilot new financing to ensure country control Lastly, Gavi should pilot new ways to channel financing to partner countries that puts them in the driver’s seat and respond to national priorities. This is especially timely amidst growing calls to shift the center of gravity for decision-making to countries. How can this be achieved? One idea is for Gavi to test a new approach that provides a consolidated envelope of resources to each country, scaled to specific criteria including population size. One portion could be dedicated to vaccine purchasing, enabling countries to base decisions on their own priorities. The second portion could be carved out for technical support and grants for health systems strengthening. With the 2030 deadline of the Sustainable Development Goals in sight, now is the time to experiment. Our collective ability to end the scourge of vaccine-preventable diseases is within reach. And Gavi – provided it is able to reform – remains one of our best bets to get there. At this crucial juncture, its leadership, board, and donors must ensure that Gavi has a fit-for-purpose model with adequate resources to deliver on the unfinished immunization agenda in a shifting global landscape. Janeen Madan Keller is deputy director of the Global Health Policy Program and a Policy Fellow at the Center for Global Development (CGD), where she leads policy-oriented research focused on the economics of global health challenges. Orin Levine has worked to accelerate the introduction of, and access to, vaccines and other proven health interventions in low- and middle-income countries for the past 30 years. He served as a member of Gavi’s board for almost nine years, representing the Bill & Melinda Gates Foundation. He currently serves as a member of the Board on Global Health for the US National Academy of Medicine, and on the Board of Directors for the National Foundation for Infectious Diseases. Image Credits: Gavi/Karel Prinsloo 2017, Gavi, the Vaccine Alliance. Posts navigation Older postsNewer posts